---
_id: '10836'
acknowledgement: This work was supported by the Austrian Science Fund (FWF) grants MCCA W1248-B30 and SFB F4606-B28 to EJJ. CP received a short-term
research fellowship of the European Federation of Immunological Societies (EFIS-IL) for a research visit at Biocruces Bizkaia Health Research Institute, Barakaldo, Spain. VKK received an EFIS-IL short-term research fellowship for a research visit at King’s College London. The
research was funded by the National Institute for Health Research (NIHR) Biomedical
Research Centre (BRC) based at Guy's and St Thomas' NHS Foundation Trust and King's
College London (IS-BRC-1215-20006) (SNK). The authors acknowledge support by the Medical Research Council
(MR/L023091/1) (SNK); Breast Cancer Now (147; KCL-BCN-Q3)(SNK); Cancer Research
UK (C30122/A11527; C30122/A15774) (SNK); Cancer Research UK King's Health Partners Centre at King's College London (C604/A25135) (SNK); CRUK/NIHR in England/DoH for Scotland, Wales and Northern Ireland Experimental Cancer Medicine Centre (C10355/A15587) (SNK). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. Additionally, this work was funded by Instituto de Salud Carlos III through the project "PI16/01223" (Co-funded by European
Regional Development Fund; “A way to make Europe”) to FB and by the Department of Health, Basque Government through the project
“2019111031” to OZ. OZ is recipient of a Sara Borrell 2017 post-doctoral contract
“CD17/00128” funded by Instituto de Salud Carlos III (Co-funded by European Social
Fund; “Investing in your future”).
article_processing_charge: No
article_type: letter_note
author:
- first_name: Christina L.
full_name: Pranger, Christina L.
last_name: Pranger
- first_name: Judit
full_name: Fazekas-Singer, Judit
id: 36432834-F248-11E8-B48F-1D18A9856A87
last_name: Fazekas-Singer
orcid: 0000-0002-8777-3502
- first_name: Verena K.
full_name: Köhler, Verena K.
last_name: Köhler
- first_name: Isabella
full_name: Pali‐Schöll, Isabella
last_name: Pali‐Schöll
- first_name: Alessandro
full_name: Fiocchi, Alessandro
last_name: Fiocchi
- first_name: Sophia N.
full_name: Karagiannis, Sophia N.
last_name: Karagiannis
- first_name: Olatz
full_name: Zenarruzabeitia, Olatz
last_name: Zenarruzabeitia
- first_name: Francisco
full_name: Borrego, Francisco
last_name: Borrego
- first_name: Erika
full_name: Jensen‐Jarolim, Erika
last_name: Jensen‐Jarolim
citation:
ama: 'Pranger CL, Singer J, Köhler VK, et al. PIPE‐cloned human IgE and IgG4 antibodies:
New tools for investigating cow’s milk allergy and tolerance. Allergy.
2021;76(5):1553-1556. doi:10.1111/all.14604'
apa: 'Pranger, C. L., Singer, J., Köhler, V. K., Pali‐Schöll, I., Fiocchi, A., Karagiannis,
S. N., … Jensen‐Jarolim, E. (2021). PIPE‐cloned human IgE and IgG4 antibodies:
New tools for investigating cow’s milk allergy and tolerance. Allergy.
Wiley. https://doi.org/10.1111/all.14604'
chicago: 'Pranger, Christina L., Judit Singer, Verena K. Köhler, Isabella Pali‐Schöll,
Alessandro Fiocchi, Sophia N. Karagiannis, Olatz Zenarruzabeitia, Francisco Borrego,
and Erika Jensen‐Jarolim. “PIPE‐cloned Human IgE and IgG4 Antibodies: New Tools
for Investigating Cow’s Milk Allergy and Tolerance.” Allergy. Wiley, 2021.
https://doi.org/10.1111/all.14604.'
ieee: 'C. L. Pranger et al., “PIPE‐cloned human IgE and IgG4 antibodies:
New tools for investigating cow’s milk allergy and tolerance,” Allergy,
vol. 76, no. 5. Wiley, pp. 1553–1556, 2021.'
ista: 'Pranger CL, Singer J, Köhler VK, Pali‐Schöll I, Fiocchi A, Karagiannis SN,
Zenarruzabeitia O, Borrego F, Jensen‐Jarolim E. 2021. PIPE‐cloned human IgE and
IgG4 antibodies: New tools for investigating cow’s milk allergy and tolerance.
Allergy. 76(5), 1553–1556.'
mla: 'Pranger, Christina L., et al. “PIPE‐cloned Human IgE and IgG4 Antibodies:
New Tools for Investigating Cow’s Milk Allergy and Tolerance.” Allergy,
vol. 76, no. 5, Wiley, 2021, pp. 1553–56, doi:10.1111/all.14604.'
short: C.L. Pranger, J. Singer, V.K. Köhler, I. Pali‐Schöll, A. Fiocchi, S.N. Karagiannis,
O. Zenarruzabeitia, F. Borrego, E. Jensen‐Jarolim, Allergy 76 (2021) 1553–1556.
date_created: 2022-03-08T11:19:05Z
date_published: 2021-05-01T00:00:00Z
date_updated: 2023-09-05T15:58:53Z
day: '01'
ddc:
- '570'
department:
- _id: Bio
doi: 10.1111/all.14604
external_id:
isi:
- '000577708800001'
pmid:
- '32990982'
file:
- access_level: open_access
checksum: 9526f9554112fc027c9f7fa540c488cd
content_type: application/pdf
creator: dernst
date_created: 2022-03-08T11:23:16Z
date_updated: 2022-03-08T11:23:16Z
file_id: '10837'
file_name: 2021_Allergy_Pranger.pdf
file_size: 626081
relation: main_file
success: 1
file_date_updated: 2022-03-08T11:23:16Z
has_accepted_license: '1'
intvolume: ' 76'
isi: 1
issue: '5'
keyword:
- Immunology
- Immunology and Allergy
language:
- iso: eng
month: '05'
oa: 1
oa_version: Published Version
page: 1553-1556
pmid: 1
publication: Allergy
publication_identifier:
eissn:
- 1398-9995
issn:
- 0105-4538
publication_status: published
publisher: Wiley
quality_controlled: '1'
scopus_import: '1'
status: public
title: 'PIPE‐cloned human IgE and IgG4 antibodies: New tools for investigating cow''s
milk allergy and tolerance'
tmp:
image: /images/cc_by.png
legal_code_url: https://creativecommons.org/licenses/by/4.0/legalcode
name: Creative Commons Attribution 4.0 International Public License (CC-BY 4.0)
short: CC BY (4.0)
type: journal_article
user_id: c635000d-4b10-11ee-a964-aac5a93f6ac1
volume: 76
year: '2021'
...
---
_id: '7864'
abstract:
- lang: eng
text: "Purpose of review: Cancer is one of the leading causes of death and the incidence
rates are constantly rising. The heterogeneity of tumors poses a big challenge
for the treatment of the disease and natural antibodies additionally affect disease
progression. The introduction of engineered mAbs for anticancer immunotherapies
has substantially improved progression-free and overall survival of cancer patients,
but little efforts have been made to exploit other antibody isotypes than IgG.\r\nRecent
findings: In order to improve these therapies, ‘next-generation antibodies’ were
engineered to enhance a specific feature of classical antibodies and form a group
of highly effective and precise therapy compounds. Advanced antibody approaches
include among others antibody-drug conjugates, glyco-engineered and Fc-engineered
antibodies, antibody fragments, radioimmunotherapy compounds, bispecific antibodies
and alternative (non-IgG) immunoglobulin classes, especially IgE.\r\nSummary:
The current review describes solutions for the needs of next-generation antibody
therapies through different approaches. Careful selection of the best-suited engineering
methodology is a key factor in developing personalized, more specific and more
efficient mAbs against cancer to improve the outcomes of cancer patients. We highlight
here the large evidence of IgE exploiting a highly cytotoxic effector arm as potential
next-generation anticancer immunotherapy."
article_processing_charge: No
article_type: original
author:
- first_name: Judit
full_name: Singer, Judit
id: 36432834-F248-11E8-B48F-1D18A9856A87
last_name: Singer
orcid: 0000-0002-8777-3502
- first_name: Josef
full_name: Singer, Josef
last_name: Singer
- first_name: Erika
full_name: Jensen-Jarolim, Erika
last_name: Jensen-Jarolim
citation:
ama: 'Singer J, Singer J, Jensen-Jarolim E. Precision medicine in clinical oncology:
the journey from IgG antibody to IgE. Current opinion in allergy and clinical
immunology. 2020;20(3):282-289. doi:10.1097/ACI.0000000000000637'
apa: 'Singer, J., Singer, J., & Jensen-Jarolim, E. (2020). Precision medicine
in clinical oncology: the journey from IgG antibody to IgE. Current Opinion
in Allergy and Clinical Immunology. Wolters Kluwer. https://doi.org/10.1097/ACI.0000000000000637'
chicago: 'Singer, Judit, Josef Singer, and Erika Jensen-Jarolim. “Precision Medicine
in Clinical Oncology: The Journey from IgG Antibody to IgE.” Current Opinion
in Allergy and Clinical Immunology. Wolters Kluwer, 2020. https://doi.org/10.1097/ACI.0000000000000637.'
ieee: 'J. Singer, J. Singer, and E. Jensen-Jarolim, “Precision medicine in clinical
oncology: the journey from IgG antibody to IgE,” Current opinion in allergy
and clinical immunology, vol. 20, no. 3. Wolters Kluwer, pp. 282–289, 2020.'
ista: 'Singer J, Singer J, Jensen-Jarolim E. 2020. Precision medicine in clinical
oncology: the journey from IgG antibody to IgE. Current opinion in allergy and
clinical immunology. 20(3), 282–289.'
mla: 'Singer, Judit, et al. “Precision Medicine in Clinical Oncology: The Journey
from IgG Antibody to IgE.” Current Opinion in Allergy and Clinical Immunology,
vol. 20, no. 3, Wolters Kluwer, 2020, pp. 282–89, doi:10.1097/ACI.0000000000000637.'
short: J. Singer, J. Singer, E. Jensen-Jarolim, Current Opinion in Allergy and Clinical
Immunology 20 (2020) 282–289.
date_created: 2020-05-17T22:00:44Z
date_published: 2020-06-01T00:00:00Z
date_updated: 2023-08-21T06:28:52Z
day: '01'
department:
- _id: Bio
doi: 10.1097/ACI.0000000000000637
external_id:
isi:
- '000561358300010'
intvolume: ' 20'
isi: 1
issue: '3'
language:
- iso: eng
month: '06'
oa_version: None
page: 282-289
publication: Current opinion in allergy and clinical immunology
publication_identifier:
eissn:
- '14736322'
publication_status: published
publisher: Wolters Kluwer
quality_controlled: '1'
scopus_import: '1'
status: public
title: 'Precision medicine in clinical oncology: the journey from IgG antibody to
IgE'
type: journal_article
user_id: 4359f0d1-fa6c-11eb-b949-802e58b17ae8
volume: 20
year: '2020'
...
---
_id: '8225'
abstract:
- lang: eng
text: Birch pollen allergy is among the most prevalent pollen allergies in Northern
and Central Europe. This IgE-mediated disease can be treated with allergen immunotherapy
(AIT), which typically gives rise to IgG antibodies inducing tolerance. Although
the main mechanisms of allergen immunotherapy (AIT) are known, questions regarding
possible Fc-mediated effects of IgG antibodies remain unanswered. This can mainly
be attributed to the unavailability of appropriate tools, i.e., well-characterised
recombinant antibodies (rAbs). We hereby aimed at providing human rAbs of several
classes for mechanistic studies and as possible candidates for passive immunotherapy.
We engineered IgE, IgG1, and IgG4 sharing the same variable region against the
major birch pollen allergen Bet v 1 using Polymerase Incomplete Primer Extension
(PIPE) cloning. We tested IgE functionality and IgG blocking capabilities using
appropriate model cell lines. In vitro studies showed IgE engagement with FcεRI
and CD23 and Bet v 1-dependent degranulation. Overall, we hereby present fully
functional, human IgE, IgG1, and IgG4 sharing the same variable region against
Bet v 1 and showcase possible applications in first mechanistic studies. Furthermore,
our IgG antibodies might be useful candidates for passive immunotherapy of birch
pollen allergy.
article_number: '5693'
article_processing_charge: No
article_type: original
author:
- first_name: Verena K.
full_name: Köhler, Verena K.
last_name: Köhler
orcid: 0000-0001-5581-398X
- first_name: Silvia
full_name: Crescioli, Silvia
last_name: Crescioli
orcid: 0000-0002-1909-5957
- first_name: Judit
full_name: Fazekas-Singer, Judit
id: 36432834-F248-11E8-B48F-1D18A9856A87
last_name: Fazekas-Singer
orcid: 0000-0002-8777-3502
- first_name: Heather J.
full_name: Bax, Heather J.
last_name: Bax
orcid: 0000-0003-0432-4160
- first_name: Gerhard
full_name: Hofer, Gerhard
last_name: Hofer
- first_name: Christina L.
full_name: Pranger, Christina L.
last_name: Pranger
- first_name: Karin
full_name: Hufnagl, Karin
last_name: Hufnagl
- first_name: Rodolfo
full_name: Bianchini, Rodolfo
last_name: Bianchini
orcid: 0000-0003-0351-6937
- first_name: Sabine
full_name: Flicker, Sabine
last_name: Flicker
orcid: 0000-0003-4768-8693
- first_name: Walter
full_name: Keller, Walter
last_name: Keller
orcid: 0000-0002-2261-958X
- first_name: Sophia N.
full_name: Karagiannis, Sophia N.
last_name: Karagiannis
orcid: 0000-0002-4100-7810
- first_name: Erika
full_name: Jensen-Jarolim, Erika
last_name: Jensen-Jarolim
orcid: 0000-0003-4019-5765
citation:
ama: 'Köhler VK, Crescioli S, Singer J, et al. Filling the antibody pipeline in
allergy: PIPE cloning of IgE, IgG1 and IgG4 against the major birch pollen allergen
Bet v 1. International Journal of Molecular Sciences. 2020;21(16). doi:10.3390/ijms21165693'
apa: 'Köhler, V. K., Crescioli, S., Singer, J., Bax, H. J., Hofer, G., Pranger,
C. L., … Jensen-Jarolim, E. (2020). Filling the antibody pipeline in allergy:
PIPE cloning of IgE, IgG1 and IgG4 against the major birch pollen allergen Bet
v 1. International Journal of Molecular Sciences. MDPI. https://doi.org/10.3390/ijms21165693'
chicago: 'Köhler, Verena K., Silvia Crescioli, Judit Singer, Heather J. Bax, Gerhard
Hofer, Christina L. Pranger, Karin Hufnagl, et al. “Filling the Antibody Pipeline
in Allergy: PIPE Cloning of IgE, IgG1 and IgG4 against the Major Birch Pollen
Allergen Bet v 1.” International Journal of Molecular Sciences. MDPI, 2020.
https://doi.org/10.3390/ijms21165693.'
ieee: 'V. K. Köhler et al., “Filling the antibody pipeline in allergy: PIPE
cloning of IgE, IgG1 and IgG4 against the major birch pollen allergen Bet v 1,”
International Journal of Molecular Sciences, vol. 21, no. 16. MDPI, 2020.'
ista: 'Köhler VK, Crescioli S, Singer J, Bax HJ, Hofer G, Pranger CL, Hufnagl K,
Bianchini R, Flicker S, Keller W, Karagiannis SN, Jensen-Jarolim E. 2020. Filling
the antibody pipeline in allergy: PIPE cloning of IgE, IgG1 and IgG4 against the
major birch pollen allergen Bet v 1. International Journal of Molecular Sciences.
21(16), 5693.'
mla: 'Köhler, Verena K., et al. “Filling the Antibody Pipeline in Allergy: PIPE
Cloning of IgE, IgG1 and IgG4 against the Major Birch Pollen Allergen Bet v 1.”
International Journal of Molecular Sciences, vol. 21, no. 16, 5693, MDPI,
2020, doi:10.3390/ijms21165693.'
short: V.K. Köhler, S. Crescioli, J. Singer, H.J. Bax, G. Hofer, C.L. Pranger, K.
Hufnagl, R. Bianchini, S. Flicker, W. Keller, S.N. Karagiannis, E. Jensen-Jarolim,
International Journal of Molecular Sciences 21 (2020).
date_created: 2020-08-10T11:47:29Z
date_published: 2020-08-08T00:00:00Z
date_updated: 2021-01-12T08:17:34Z
day: '08'
ddc:
- '570'
doi: 10.3390/ijms21165693
extern: '1'
external_id:
pmid:
- '32784509'
file:
- access_level: open_access
checksum: dac7ccef7cdcea9be292664d8c488425
content_type: application/pdf
creator: dernst
date_created: 2020-09-10T07:06:22Z
date_updated: 2020-09-10T07:06:22Z
file_id: '8356'
file_name: 2020_IntMolecSciences_Koehler.pdf
file_size: 2680908
relation: main_file
success: 1
file_date_updated: 2020-09-10T07:06:22Z
has_accepted_license: '1'
intvolume: ' 21'
issue: '16'
language:
- iso: eng
month: '08'
oa: 1
oa_version: Published Version
pmid: 1
publication: International Journal of Molecular Sciences
publication_identifier:
issn:
- 1422-0067
publication_status: published
publisher: MDPI
quality_controlled: '1'
status: public
title: 'Filling the antibody pipeline in allergy: PIPE cloning of IgE, IgG1 and IgG4
against the major birch pollen allergen Bet v 1'
tmp:
image: /images/cc_by.png
legal_code_url: https://creativecommons.org/licenses/by/4.0/legalcode
name: Creative Commons Attribution 4.0 International Public License (CC-BY 4.0)
short: CC BY (4.0)
type: journal_article
user_id: 2DF688A6-F248-11E8-B48F-1D18A9856A87
volume: 21
year: '2020'
...
---
_id: '8226'
article_processing_charge: No
article_type: letter_note
author:
- first_name: Jelena
full_name: Gotovina, Jelena
last_name: Gotovina
orcid: 0000-0003-1503-5276
- first_name: Rodolfo
full_name: Bianchini, Rodolfo
last_name: Bianchini
orcid: 0000-0003-0351-6937
- first_name: Judit
full_name: Fazekas-Singer, Judit
id: 36432834-F248-11E8-B48F-1D18A9856A87
last_name: Fazekas-Singer
orcid: 0000-0002-8777-3502
- first_name: Ina
full_name: Herrmann, Ina
last_name: Herrmann
orcid: 0000-0003-2772-9144
- first_name: Giulia
full_name: Pellizzari, Giulia
last_name: Pellizzari
orcid: 0000-0003-0387-1912
- first_name: Ian D.
full_name: Haidl, Ian D.
last_name: Haidl
orcid: 0000-0002-5301-0822
- first_name: Karin
full_name: Hufnagl, Karin
last_name: Hufnagl
orcid: 0000-0002-2288-2468
- first_name: Sophia N.
full_name: Karagiannis, Sophia N.
last_name: Karagiannis
orcid: 0000-0002-4100-7810
- first_name: Jean S.
full_name: Marshall, Jean S.
last_name: Marshall
orcid: 0000-0002-5642-1379
- first_name: Erika
full_name: Jensen‐Jarolim, Erika
last_name: Jensen‐Jarolim
orcid: 0000-0003-4019-5765
citation:
ama: Gotovina J, Bianchini R, Singer J, et al. Epinephrine drives human M2a allergic
macrophages to a regulatory phenotype reducing mast cell degranulation in vitro.
Allergy. 2020. doi:10.1111/all.14299
apa: Gotovina, J., Bianchini, R., Singer, J., Herrmann, I., Pellizzari, G., Haidl,
I. D., … Jensen‐Jarolim, E. (2020). Epinephrine drives human M2a allergic macrophages
to a regulatory phenotype reducing mast cell degranulation in vitro. Allergy.
Wiley. https://doi.org/10.1111/all.14299
chicago: Gotovina, Jelena, Rodolfo Bianchini, Judit Singer, Ina Herrmann, Giulia
Pellizzari, Ian D. Haidl, Karin Hufnagl, Sophia N. Karagiannis, Jean S. Marshall,
and Erika Jensen‐Jarolim. “Epinephrine Drives Human M2a Allergic Macrophages to
a Regulatory Phenotype Reducing Mast Cell Degranulation in Vitro.” Allergy.
Wiley, 2020. https://doi.org/10.1111/all.14299.
ieee: J. Gotovina et al., “Epinephrine drives human M2a allergic macrophages
to a regulatory phenotype reducing mast cell degranulation in vitro,” Allergy.
Wiley, 2020.
ista: Gotovina J, Bianchini R, Singer J, Herrmann I, Pellizzari G, Haidl ID, Hufnagl
K, Karagiannis SN, Marshall JS, Jensen‐Jarolim E. 2020. Epinephrine drives human
M2a allergic macrophages to a regulatory phenotype reducing mast cell degranulation
in vitro. Allergy.
mla: Gotovina, Jelena, et al. “Epinephrine Drives Human M2a Allergic Macrophages
to a Regulatory Phenotype Reducing Mast Cell Degranulation in Vitro.” Allergy,
Wiley, 2020, doi:10.1111/all.14299.
short: J. Gotovina, R. Bianchini, J. Singer, I. Herrmann, G. Pellizzari, I.D. Haidl,
K. Hufnagl, S.N. Karagiannis, J.S. Marshall, E. Jensen‐Jarolim, Allergy (2020).
date_created: 2020-08-10T11:50:30Z
date_published: 2020-04-04T00:00:00Z
date_updated: 2021-01-12T08:17:35Z
day: '04'
doi: 10.1111/all.14299
extern: '1'
language:
- iso: eng
main_file_link:
- open_access: '1'
url: https://doi.org/10.1111/all.14299
month: '04'
oa: 1
oa_version: Published Version
publication: Allergy
publication_identifier:
issn:
- 0105-4538
- 1398-9995
publication_status: epub_ahead
publisher: Wiley
quality_controlled: '1'
status: public
title: Epinephrine drives human M2a allergic macrophages to a regulatory phenotype
reducing mast cell degranulation in vitro
type: journal_article
user_id: 2DF688A6-F248-11E8-B48F-1D18A9856A87
year: '2020'
...
---
_id: '8227'
article_processing_charge: No
article_type: letter_note
author:
- first_name: Kristina M.
full_name: Ilieva, Kristina M.
last_name: Ilieva
- first_name: Judit
full_name: Fazekas-Singer, Judit
id: 36432834-F248-11E8-B48F-1D18A9856A87
last_name: Fazekas-Singer
orcid: 0000-0002-8777-3502
- first_name: Heather J.
full_name: Bax, Heather J.
last_name: Bax
- first_name: Silvia
full_name: Crescioli, Silvia
last_name: Crescioli
- first_name: Laura
full_name: Montero‐Morales, Laura
last_name: Montero‐Morales
- first_name: Silvia
full_name: Mele, Silvia
last_name: Mele
- first_name: Heng Sheng
full_name: Sow, Heng Sheng
last_name: Sow
- first_name: Chara
full_name: Stavraka, Chara
last_name: Stavraka
- first_name: Debra H.
full_name: Josephs, Debra H.
last_name: Josephs
- first_name: James F.
full_name: Spicer, James F.
last_name: Spicer
- first_name: Herta
full_name: Steinkellner, Herta
last_name: Steinkellner
orcid: 0000-0003-4823-1505
- first_name: Erika
full_name: Jensen‐Jarolim, Erika
last_name: Jensen‐Jarolim
orcid: 0000-0003-4019-5765
- first_name: Andrew N. J.
full_name: Tutt, Andrew N. J.
last_name: Tutt
orcid: 0000-0001-8715-2901
- first_name: Sophia N.
full_name: Karagiannis, Sophia N.
last_name: Karagiannis
orcid: 0000-0002-4100-7810
citation:
ama: 'Ilieva KM, Singer J, Bax HJ, et al. AllergoOncology: Expression platform development
and functional profiling of an anti‐HER2 IgE antibody. Allergy. 2019;74(10):1985-1989.
doi:10.1111/all.13818'
apa: 'Ilieva, K. M., Singer, J., Bax, H. J., Crescioli, S., Montero‐Morales, L.,
Mele, S., … Karagiannis, S. N. (2019). AllergoOncology: Expression platform development
and functional profiling of an anti‐HER2 IgE antibody. Allergy. Wiley.
https://doi.org/10.1111/all.13818'
chicago: 'Ilieva, Kristina M., Judit Singer, Heather J. Bax, Silvia Crescioli, Laura
Montero‐Morales, Silvia Mele, Heng Sheng Sow, et al. “AllergoOncology: Expression
Platform Development and Functional Profiling of an Anti‐HER2 IgE Antibody.” Allergy.
Wiley, 2019. https://doi.org/10.1111/all.13818.'
ieee: 'K. M. Ilieva et al., “AllergoOncology: Expression platform development
and functional profiling of an anti‐HER2 IgE antibody,” Allergy, vol. 74,
no. 10. Wiley, pp. 1985–1989, 2019.'
ista: 'Ilieva KM, Singer J, Bax HJ, Crescioli S, Montero‐Morales L, Mele S, Sow
HS, Stavraka C, Josephs DH, Spicer JF, Steinkellner H, Jensen‐Jarolim E, Tutt
ANJ, Karagiannis SN. 2019. AllergoOncology: Expression platform development and
functional profiling of an anti‐HER2 IgE antibody. Allergy. 74(10), 1985–1989.'
mla: 'Ilieva, Kristina M., et al. “AllergoOncology: Expression Platform Development
and Functional Profiling of an Anti‐HER2 IgE Antibody.” Allergy, vol. 74,
no. 10, Wiley, 2019, pp. 1985–89, doi:10.1111/all.13818.'
short: K.M. Ilieva, J. Singer, H.J. Bax, S. Crescioli, L. Montero‐Morales, S. Mele,
H.S. Sow, C. Stavraka, D.H. Josephs, J.F. Spicer, H. Steinkellner, E. Jensen‐Jarolim,
A.N.J. Tutt, S.N. Karagiannis, Allergy 74 (2019) 1985–1989.
date_created: 2020-08-10T11:50:42Z
date_published: 2019-10-01T00:00:00Z
date_updated: 2021-01-12T08:17:35Z
day: '01'
doi: 10.1111/all.13818
extern: '1'
intvolume: ' 74'
issue: '10'
language:
- iso: eng
main_file_link:
- open_access: '1'
url: https://doi.org/10.1111/all.13818
month: '10'
oa: 1
oa_version: Published Version
page: 1985-1989
publication: Allergy
publication_identifier:
issn:
- 0105-4538
- 1398-9995
publication_status: published
publisher: Wiley
quality_controlled: '1'
status: public
title: 'AllergoOncology: Expression platform development and functional profiling
of an anti‐HER2 IgE antibody'
type: journal_article
user_id: 2DF688A6-F248-11E8-B48F-1D18A9856A87
volume: 74
year: '2019'
...
---
_id: '8228'
abstract:
- lang: eng
text: "Background: Atopics have a lower risk for malignancies, and IgE targeted
to tumors is superior to IgG in fighting cancer. Whether IgE-mediated innate or
adaptive immune surveillance can confer protection against tumors remains unclear.\r\nObjective:
We aimed to investigate the effects of active and passive immunotherapy to the
tumor-associated antigen HER-2 in three murine models differing in Epsilon-B-cell-receptor
expression affecting the levels of expressed IgE.\r\nMethods: We compared the
levels of several serum specific anti-HER-2 antibodies (IgE, IgG1, IgG2a, IgG2b,
IgA) and the survival rates in low-IgE ΔM1M2 mice lacking the transmembrane/cytoplasmic
domain of Epsilon-B-cell-receptors expressing reduced IgE levels, high-IgE KN1
mice expressing chimeric Epsilon-Gamma1-B-cell receptors with 4-6-fold elevated
serum IgE levels, and wild type (WT) BALB/c. Prior engrafting mice with D2F2/E2
mammary tumors overexpressing HER-2, mice were vaccinated with HER-2 or vehicle
control PBS using the Th2-adjuvant Al(OH)3 (active immunotherapy), or treated
with the murine anti-HER-2 IgG1 antibody 4D5 (passive immunotherapy).\r\nResults:
Overall, among the three strains of mice, HER-2 vaccination induced significantly
higher levels of HER-2 specific IgE and IgG1 in high-IgE KN1, while low-IgE ΔM1M2
mice had higher IgG2a levels. HER-2 vaccination and passive immunotherapy prolonged
the survival in tumor-grafted WT and low-IgE ΔM1M2 strains compared with treatment
controls; active vaccination provided the highest benefit. Notably, untreated
high-IgE KN1 mice displayed the longest survival of all strains, which could not
be further extended by active or passive immunotherapy.\r\nConclusion: Active
and passive immunotherapies prolong survival in wild type and low-IgE ΔM1M2 mice
engrafted with mammary tumors. High-IgE KN1 mice have an innate survival benefit
following tumor challenge."
article_number: '100044'
article_processing_charge: No
article_type: original
author:
- first_name: Josef
full_name: Singer, Josef
last_name: Singer
orcid: 0000-0002-8701-2412
- first_name: Gertrude
full_name: Achatz-Straussberger, Gertrude
last_name: Achatz-Straussberger
- first_name: Anna
full_name: Bentley-Lukschal, Anna
last_name: Bentley-Lukschal
- first_name: Judit
full_name: Fazekas-Singer, Judit
id: 36432834-F248-11E8-B48F-1D18A9856A87
last_name: Fazekas-Singer
orcid: 0000-0002-8777-3502
- first_name: Gernot
full_name: Achatz, Gernot
last_name: Achatz
- first_name: Sophia N.
full_name: Karagiannis, Sophia N.
last_name: Karagiannis
- first_name: Erika
full_name: Jensen-Jarolim, Erika
last_name: Jensen-Jarolim
citation:
ama: 'Singer J, Achatz-Straussberger G, Bentley-Lukschal A, et al. AllergoOncology:
High innate IgE levels are decisive for the survival of cancer-bearing mice. World
Allergy Organization Journal. 2019;12(7). doi:10.1016/j.waojou.2019.100044'
apa: 'Singer, J., Achatz-Straussberger, G., Bentley-Lukschal, A., Singer, J., Achatz,
G., Karagiannis, S. N., & Jensen-Jarolim, E. (2019). AllergoOncology: High
innate IgE levels are decisive for the survival of cancer-bearing mice. World
Allergy Organization Journal. Elsevier. https://doi.org/10.1016/j.waojou.2019.100044'
chicago: 'Singer, Josef, Gertrude Achatz-Straussberger, Anna Bentley-Lukschal, Judit
Singer, Gernot Achatz, Sophia N. Karagiannis, and Erika Jensen-Jarolim. “AllergoOncology:
High Innate IgE Levels Are Decisive for the Survival of Cancer-Bearing Mice.”
World Allergy Organization Journal. Elsevier, 2019. https://doi.org/10.1016/j.waojou.2019.100044.'
ieee: 'J. Singer et al., “AllergoOncology: High innate IgE levels are decisive
for the survival of cancer-bearing mice,” World Allergy Organization Journal,
vol. 12, no. 7. Elsevier, 2019.'
ista: 'Singer J, Achatz-Straussberger G, Bentley-Lukschal A, Singer J, Achatz G,
Karagiannis SN, Jensen-Jarolim E. 2019. AllergoOncology: High innate IgE levels
are decisive for the survival of cancer-bearing mice. World Allergy Organization
Journal. 12(7), 100044.'
mla: 'Singer, Josef, et al. “AllergoOncology: High Innate IgE Levels Are Decisive
for the Survival of Cancer-Bearing Mice.” World Allergy Organization Journal,
vol. 12, no. 7, 100044, Elsevier, 2019, doi:10.1016/j.waojou.2019.100044.'
short: J. Singer, G. Achatz-Straussberger, A. Bentley-Lukschal, J. Singer, G. Achatz,
S.N. Karagiannis, E. Jensen-Jarolim, World Allergy Organization Journal 12 (2019).
date_created: 2020-08-10T11:50:54Z
date_published: 2019-07-29T00:00:00Z
date_updated: 2021-01-12T08:17:36Z
day: '29'
doi: 10.1016/j.waojou.2019.100044
extern: '1'
intvolume: ' 12'
issue: '7'
language:
- iso: eng
main_file_link:
- open_access: '1'
url: https://doi.org/10.1016/j.waojou.2019.100044
month: '07'
oa: 1
oa_version: Published Version
publication: World Allergy Organization Journal
publication_identifier:
issn:
- 1939-4551
publication_status: published
publisher: Elsevier
quality_controlled: '1'
status: public
title: 'AllergoOncology: High innate IgE levels are decisive for the survival of cancer-bearing
mice'
type: journal_article
user_id: 2DF688A6-F248-11E8-B48F-1D18A9856A87
volume: 12
year: '2019'
...
---
_id: '8229'
abstract:
- lang: eng
text: Food proteins may get nitrated by various exogenous or endogenous mechanisms.
As individuals might get recurrently exposed to nitrated proteins via daily diet,
we aimed to investigate the effect of repeatedly ingested nitrated food proteins
on the subsequent immune response in non-allergic and allergic mice using the
milk allergen beta-lactoglobulin (BLG) as model food protein in a mouse model.
Evaluating the presence of nitrated proteins in food, we could detect 3-nitrotyrosine
(3-NT) in extracts of different foods and in stomach content extracts of non-allergic
mice under physiological conditions. Chemically nitrated BLG (BLGn) exhibited
enhanced susceptibility to degradation in simulated gastric fluid experiments
compared to untreated BLG (BLGu). Gavage of BLGn to non-allergic animals increased
interferon-γ and interleukin-10 release of stimulated spleen cells and led to
the formation of BLG-specific serum IgA. Allergic mice receiving three oral gavages
of BLGn had higher levels of mouse mast cell protease-1 (mMCP-1) compared to allergic
mice receiving BLGu. Regardless of the preceding immune status, non-allergic or
allergic, repeatedly ingested nitrated food proteins seem to considerably influence
the subsequent immune response.
article_number: '2463'
article_processing_charge: No
article_type: original
author:
- first_name: Anna S.
full_name: Ondracek, Anna S.
last_name: Ondracek
orcid: 0000-0001-7625-3651
- first_name: Denise
full_name: Heiden, Denise
last_name: Heiden
- first_name: Gertie J.
full_name: Oostingh, Gertie J.
last_name: Oostingh
- first_name: Elisabeth
full_name: Fuerst, Elisabeth
last_name: Fuerst
- first_name: Judit
full_name: Fazekas-Singer, Judit
id: 36432834-F248-11E8-B48F-1D18A9856A87
last_name: Fazekas-Singer
orcid: 0000-0002-8777-3502
- first_name: Cornelia
full_name: Bergmayr, Cornelia
last_name: Bergmayr
- first_name: Johanna
full_name: Rohrhofer, Johanna
last_name: Rohrhofer
orcid: 0000-0002-2783-2099
- first_name: Erika
full_name: Jensen-Jarolim, Erika
last_name: Jensen-Jarolim
orcid: 0000-0003-4019-5765
- first_name: Albert
full_name: Duschl, Albert
last_name: Duschl
orcid: 0000-0002-7034-9860
- first_name: Eva
full_name: Untersmayr, Eva
last_name: Untersmayr
orcid: 0000-0002-1963-499X
citation:
ama: Ondracek AS, Heiden D, Oostingh GJ, et al. Immune effects of the nitrated food
allergen beta-lactoglobulin in an experimental food allergy model. Nutrients.
2019;11(10). doi:10.3390/nu11102463
apa: Ondracek, A. S., Heiden, D., Oostingh, G. J., Fuerst, E., Singer, J., Bergmayr,
C., … Untersmayr, E. (2019). Immune effects of the nitrated food allergen beta-lactoglobulin
in an experimental food allergy model. Nutrients. MDPI. https://doi.org/10.3390/nu11102463
chicago: Ondracek, Anna S., Denise Heiden, Gertie J. Oostingh, Elisabeth Fuerst,
Judit Singer, Cornelia Bergmayr, Johanna Rohrhofer, Erika Jensen-Jarolim, Albert
Duschl, and Eva Untersmayr. “Immune Effects of the Nitrated Food Allergen Beta-Lactoglobulin
in an Experimental Food Allergy Model.” Nutrients. MDPI, 2019. https://doi.org/10.3390/nu11102463.
ieee: A. S. Ondracek et al., “Immune effects of the nitrated food allergen
beta-lactoglobulin in an experimental food allergy model,” Nutrients, vol.
11, no. 10. MDPI, 2019.
ista: Ondracek AS, Heiden D, Oostingh GJ, Fuerst E, Singer J, Bergmayr C, Rohrhofer
J, Jensen-Jarolim E, Duschl A, Untersmayr E. 2019. Immune effects of the nitrated
food allergen beta-lactoglobulin in an experimental food allergy model. Nutrients.
11(10), 2463.
mla: Ondracek, Anna S., et al. “Immune Effects of the Nitrated Food Allergen Beta-Lactoglobulin
in an Experimental Food Allergy Model.” Nutrients, vol. 11, no. 10, 2463,
MDPI, 2019, doi:10.3390/nu11102463.
short: A.S. Ondracek, D. Heiden, G.J. Oostingh, E. Fuerst, J. Singer, C. Bergmayr,
J. Rohrhofer, E. Jensen-Jarolim, A. Duschl, E. Untersmayr, Nutrients 11 (2019).
date_created: 2020-08-10T11:51:04Z
date_published: 2019-10-15T00:00:00Z
date_updated: 2021-01-12T08:17:36Z
day: '15'
doi: 10.3390/nu11102463
extern: '1'
intvolume: ' 11'
issue: '10'
language:
- iso: eng
main_file_link:
- open_access: '1'
url: https://doi.org/10.3390/nu11102463
month: '10'
oa: 1
oa_version: Published Version
publication: Nutrients
publication_identifier:
issn:
- 2072-6643
publication_status: published
publisher: MDPI
quality_controlled: '1'
status: public
title: Immune effects of the nitrated food allergen beta-lactoglobulin in an experimental
food allergy model
type: journal_article
user_id: 2DF688A6-F248-11E8-B48F-1D18A9856A87
volume: 11
year: '2019'
...
---
_id: '8231'
article_processing_charge: No
article_type: letter_note
author:
- first_name: Judit
full_name: Fazekas-Singer, Judit
id: 36432834-F248-11E8-B48F-1D18A9856A87
last_name: Fazekas-Singer
orcid: 0000-0002-8777-3502
- first_name: Josef
full_name: Singer, Josef
last_name: Singer
- first_name: Kristina M.
full_name: Ilieva, Kristina M.
last_name: Ilieva
- first_name: Miroslawa
full_name: Matz, Miroslawa
last_name: Matz
- first_name: Ina
full_name: Herrmann, Ina
last_name: Herrmann
- first_name: Edzard
full_name: Spillner, Edzard
last_name: Spillner
- first_name: Sophia N.
full_name: Karagiannis, Sophia N.
last_name: Karagiannis
- first_name: Erika
full_name: Jensen-Jarolim, Erika
last_name: Jensen-Jarolim
citation:
ama: 'Singer J, Singer J, Ilieva KM, et al. AllergoOncology: Generating a canine
anticancer IgE against the epidermal growth factor receptor. Journal of Allergy
and Clinical Immunology. 2018;142(3):973-976.e11. doi:10.1016/j.jaci.2018.04.021'
apa: 'Singer, J., Singer, J., Ilieva, K. M., Matz, M., Herrmann, I., Spillner, E.,
… Jensen-Jarolim, E. (2018). AllergoOncology: Generating a canine anticancer IgE
against the epidermal growth factor receptor. Journal of Allergy and Clinical
Immunology. Elsevier. https://doi.org/10.1016/j.jaci.2018.04.021'
chicago: 'Singer, Judit, Josef Singer, Kristina M. Ilieva, Miroslawa Matz, Ina Herrmann,
Edzard Spillner, Sophia N. Karagiannis, and Erika Jensen-Jarolim. “AllergoOncology:
Generating a Canine Anticancer IgE against the Epidermal Growth Factor Receptor.”
Journal of Allergy and Clinical Immunology. Elsevier, 2018. https://doi.org/10.1016/j.jaci.2018.04.021.'
ieee: 'J. Singer et al., “AllergoOncology: Generating a canine anticancer
IgE against the epidermal growth factor receptor,” Journal of Allergy and Clinical
Immunology, vol. 142, no. 3. Elsevier, p. 973–976.e11, 2018.'
ista: 'Singer J, Singer J, Ilieva KM, Matz M, Herrmann I, Spillner E, Karagiannis
SN, Jensen-Jarolim E. 2018. AllergoOncology: Generating a canine anticancer IgE
against the epidermal growth factor receptor. Journal of Allergy and Clinical
Immunology. 142(3), 973–976.e11.'
mla: 'Singer, Judit, et al. “AllergoOncology: Generating a Canine Anticancer IgE
against the Epidermal Growth Factor Receptor.” Journal of Allergy and Clinical
Immunology, vol. 142, no. 3, Elsevier, 2018, p. 973–976.e11, doi:10.1016/j.jaci.2018.04.021.'
short: J. Singer, J. Singer, K.M. Ilieva, M. Matz, I. Herrmann, E. Spillner, S.N.
Karagiannis, E. Jensen-Jarolim, Journal of Allergy and Clinical Immunology 142
(2018) 973–976.e11.
date_created: 2020-08-10T11:51:36Z
date_published: 2018-09-01T00:00:00Z
date_updated: 2021-01-12T08:17:37Z
day: '01'
doi: 10.1016/j.jaci.2018.04.021
extern: '1'
intvolume: ' 142'
issue: '3'
language:
- iso: eng
main_file_link:
- open_access: '1'
url: https://doi.org/10.1016/j.jaci.2018.04.021
month: '09'
oa: 1
oa_version: Published Version
page: 973-976.e11
publication: Journal of Allergy and Clinical Immunology
publication_identifier:
issn:
- 0091-6749
publication_status: published
publisher: Elsevier
quality_controlled: '1'
status: public
title: 'AllergoOncology: Generating a canine anticancer IgE against the epidermal
growth factor receptor'
type: journal_article
user_id: 2DF688A6-F248-11E8-B48F-1D18A9856A87
volume: 142
year: '2018'
...
---
_id: '8232'
abstract:
- lang: eng
text: 'Anti-epidermal growth factor receptor (EGFR) antibody therapy is used in
EGFR expressing cancers including lung, colon, head and neck, and bladder cancers,
however results have been modest. Near infrared photoimmunotherapy (NIR-PIT) is
a highly selective tumor treatment that employs an antibody-photo-absorber conjugate
which is activated by NIR light. NIR-PIT is in clinical trials in patients with
recurrent head and neck cancers using cetuximab-IR700 as the conjugate. However,
its use has otherwise been restricted to mouse models. This is an effort to explore
larger animal models with NIR-PIT. We describe the use of a recombinant canine
anti-EGFR monoclonal antibody (mAb), can225IgG, conjugated to the photo-absorber,
IR700DX, in three EGFR expressing canine transitional cell carcinoma (TCC) cell
lines as a prelude to possible canine clinical studies. Can225-IR700 conjugate
showed specific binding and cell-specific killing after NIR-PIT on EGFR expressing
cells in vitro. In the in vivo study, can225-IR700 conjugate demonstrated accumulation
of the fluorescent conjugate with high tumor-to-background ratio. Tumor-bearing
mice were separated into 4 groups: (1) no treatment; (2) 100 μg of can225-IR700
i.v. only; (3) NIR light exposure only; (4) 100 μg of can225-IR700 i.v., NIR light
exposure. Tumor growth was significantly inhibited by NIR-PIT treatment compared
with the other groups (p < 0.001), and significantly prolonged survival was achieved
(p < 0.001 vs. other groups) in the treatment groups. In conclusion, NIR-PIT with
can225-IR700 is a promising treatment for canine EGFR-expressing cancers, including
invasive transitional cell carcinoma in pet dogs, that could provide a pathway
to translation to humans.'
article_processing_charge: No
article_type: original
author:
- first_name: Tadanobu
full_name: Nagaya, Tadanobu
last_name: Nagaya
- first_name: Shuhei
full_name: Okuyama, Shuhei
last_name: Okuyama
- first_name: Fusa
full_name: Ogata, Fusa
last_name: Ogata
- first_name: Yasuhiro
full_name: Maruoka, Yasuhiro
last_name: Maruoka
- first_name: Deborah W.
full_name: Knapp, Deborah W.
last_name: Knapp
- first_name: Sophia N.
full_name: Karagiannis, Sophia N.
last_name: Karagiannis
- first_name: Judit
full_name: Fazekas-Singer, Judit
id: 36432834-F248-11E8-B48F-1D18A9856A87
last_name: Fazekas-Singer
orcid: 0000-0002-8777-3502
- first_name: Peter L.
full_name: Choyke, Peter L.
last_name: Choyke
- first_name: Amy K.
full_name: LeBlanc, Amy K.
last_name: LeBlanc
- first_name: Erika
full_name: Jensen-Jarolim, Erika
last_name: Jensen-Jarolim
- first_name: Hisataka
full_name: Kobayashi, Hisataka
last_name: Kobayashi
citation:
ama: Nagaya T, Okuyama S, Ogata F, et al. Near infrared photoimmunotherapy targeting
bladder cancer with a canine anti-epidermal growth factor receptor (EGFR) antibody.
Oncotarget. 2018;9:19026-19038. doi:10.18632/oncotarget.24876
apa: Nagaya, T., Okuyama, S., Ogata, F., Maruoka, Y., Knapp, D. W., Karagiannis,
S. N., … Kobayashi, H. (2018). Near infrared photoimmunotherapy targeting bladder
cancer with a canine anti-epidermal growth factor receptor (EGFR) antibody. Oncotarget.
Impact Journals. https://doi.org/10.18632/oncotarget.24876
chicago: Nagaya, Tadanobu, Shuhei Okuyama, Fusa Ogata, Yasuhiro Maruoka, Deborah
W. Knapp, Sophia N. Karagiannis, Judit Singer, et al. “Near Infrared Photoimmunotherapy
Targeting Bladder Cancer with a Canine Anti-Epidermal Growth Factor Receptor (EGFR)
Antibody.” Oncotarget. Impact Journals, 2018. https://doi.org/10.18632/oncotarget.24876.
ieee: T. Nagaya et al., “Near infrared photoimmunotherapy targeting bladder
cancer with a canine anti-epidermal growth factor receptor (EGFR) antibody,” Oncotarget,
vol. 9. Impact Journals, pp. 19026–19038, 2018.
ista: Nagaya T, Okuyama S, Ogata F, Maruoka Y, Knapp DW, Karagiannis SN, Singer
J, Choyke PL, LeBlanc AK, Jensen-Jarolim E, Kobayashi H. 2018. Near infrared photoimmunotherapy
targeting bladder cancer with a canine anti-epidermal growth factor receptor (EGFR)
antibody. Oncotarget. 9, 19026–19038.
mla: Nagaya, Tadanobu, et al. “Near Infrared Photoimmunotherapy Targeting Bladder
Cancer with a Canine Anti-Epidermal Growth Factor Receptor (EGFR) Antibody.” Oncotarget,
vol. 9, Impact Journals, 2018, pp. 19026–38, doi:10.18632/oncotarget.24876.
short: T. Nagaya, S. Okuyama, F. Ogata, Y. Maruoka, D.W. Knapp, S.N. Karagiannis,
J. Singer, P.L. Choyke, A.K. LeBlanc, E. Jensen-Jarolim, H. Kobayashi, Oncotarget
9 (2018) 19026–19038.
date_created: 2020-08-10T11:52:54Z
date_published: 2018-04-10T00:00:00Z
date_updated: 2021-01-12T08:17:37Z
day: '10'
doi: 10.18632/oncotarget.24876
extern: '1'
intvolume: ' 9'
language:
- iso: eng
main_file_link:
- open_access: '1'
url: https://doi.org/10.18632/oncotarget.24876
month: '04'
oa: 1
oa_version: Published Version
page: 19026-19038
publication: Oncotarget
publication_identifier:
eissn:
- 1949-2553
publication_status: published
publisher: Impact Journals
quality_controlled: '1'
status: public
title: Near infrared photoimmunotherapy targeting bladder cancer with a canine anti-epidermal
growth factor receptor (EGFR) antibody
type: journal_article
user_id: 2DF688A6-F248-11E8-B48F-1D18A9856A87
volume: 9
year: '2018'
...
---
_id: '8233'
abstract:
- lang: eng
text: The M2a subtype of macrophages plays an important role in human immunoglobulin
E (IgE-mediated allergies) and other Th2 type immune reactions. In contrast, very
little is known about these cells in the dog. Here we describe an in vitro method
to activate canine histiocytic DH82 cells and primary canine monocyte-derived
macrophages (MDMs) toward the M2a macrophages using human cytokines. For a side-by-side
comparison, we compared the canine cells to human MDMs, and the human monocytic
cell line U937 activated towards M1 and M2a cells on the cellular and molecular
level. In analogy to activated human M2a cells, canine M2a, differentiated from
both DH82 and MDMs, showed an increase in CD206 surface receptor expression compared
to M1. Interestingly, canine M2a, but not M1 derived from MDM, upregulated the
high-affinity IgE receptor (FcεRI). Transcription levels of M2a-associated genes
(IL10, CCL22, TGFβ, CD163) showed a diverse pattern between the human and dog
species, whereas M1 genes (IDO1, CXCL11, IL6, TNF-α) were similarly upregulated
in canine and human M1 cells (cell lines and MDMs). We suggest that our novel
in vitro method will be suitable in comparative allergology studies focussing
on macrophages.
article_processing_charge: No
article_type: original
author:
- first_name: Ina
full_name: Herrmann, Ina
last_name: Herrmann
- first_name: Jelena
full_name: Gotovina, Jelena
last_name: Gotovina
- first_name: Judit
full_name: Fazekas-Singer, Judit
id: 36432834-F248-11E8-B48F-1D18A9856A87
last_name: Fazekas-Singer
orcid: 0000-0002-8777-3502
- first_name: Michael B.
full_name: Fischer, Michael B.
last_name: Fischer
- first_name: Karin
full_name: Hufnagl, Karin
last_name: Hufnagl
- first_name: Rodolfo
full_name: Bianchini, Rodolfo
last_name: Bianchini
- first_name: Erika
full_name: Jensen-Jarolim, Erika
last_name: Jensen-Jarolim
citation:
ama: Herrmann I, Gotovina J, Singer J, et al. Canine macrophages can like human
macrophages be in vitro activated toward the M2a subtype relevant in allergy.
Developmental & Comparative Immunology. 2018;82(5):118-127. doi:10.1016/j.dci.2018.01.005
apa: Herrmann, I., Gotovina, J., Singer, J., Fischer, M. B., Hufnagl, K., Bianchini,
R., & Jensen-Jarolim, E. (2018). Canine macrophages can like human macrophages
be in vitro activated toward the M2a subtype relevant in allergy. Developmental
& Comparative Immunology. Elsevier. https://doi.org/10.1016/j.dci.2018.01.005
chicago: Herrmann, Ina, Jelena Gotovina, Judit Singer, Michael B. Fischer, Karin
Hufnagl, Rodolfo Bianchini, and Erika Jensen-Jarolim. “Canine Macrophages Can
like Human Macrophages Be in Vitro Activated toward the M2a Subtype Relevant in
Allergy.” Developmental & Comparative Immunology. Elsevier, 2018. https://doi.org/10.1016/j.dci.2018.01.005.
ieee: I. Herrmann et al., “Canine macrophages can like human macrophages
be in vitro activated toward the M2a subtype relevant in allergy,” Developmental
& Comparative Immunology, vol. 82, no. 5. Elsevier, pp. 118–127, 2018.
ista: Herrmann I, Gotovina J, Singer J, Fischer MB, Hufnagl K, Bianchini R, Jensen-Jarolim
E. 2018. Canine macrophages can like human macrophages be in vitro activated toward
the M2a subtype relevant in allergy. Developmental & Comparative Immunology.
82(5), 118–127.
mla: Herrmann, Ina, et al. “Canine Macrophages Can like Human Macrophages Be in Vitro
Activated toward the M2a Subtype Relevant in Allergy.” Developmental &
Comparative Immunology, vol. 82, no. 5, Elsevier, 2018, pp. 118–27, doi:10.1016/j.dci.2018.01.005.
short: I. Herrmann, J. Gotovina, J. Singer, M.B. Fischer, K. Hufnagl, R. Bianchini,
E. Jensen-Jarolim, Developmental & Comparative Immunology 82 (2018) 118–127.
date_created: 2020-08-10T11:53:01Z
date_published: 2018-05-01T00:00:00Z
date_updated: 2021-01-12T08:17:38Z
day: '01'
doi: 10.1016/j.dci.2018.01.005
extern: '1'
intvolume: ' 82'
issue: '5'
language:
- iso: eng
main_file_link:
- open_access: '1'
url: https://doi.org/10.1016/j.dci.2018.01.005
month: '05'
oa: 1
oa_version: Published Version
page: 118-127
publication: Developmental & Comparative Immunology
publication_identifier:
issn:
- 0145-305X
publication_status: published
publisher: Elsevier
quality_controlled: '1'
status: public
title: Canine macrophages can like human macrophages be in vitro activated toward
the M2a subtype relevant in allergy
type: journal_article
user_id: 2DF688A6-F248-11E8-B48F-1D18A9856A87
volume: 82
year: '2018'
...
---
_id: '8234'
abstract:
- lang: eng
text: Molecular imaging probes such as PET-tracers have the potential to improve
the accuracy of tumor characterization by directly visualizing the biochemical
situation. Thus, molecular changes can be detected early before morphological
manifestation. The A3 adenosine receptor (A3AR) is described to be highly expressed
in colon cancer cell lines and human colorectal cancer (CRC), suggesting this
receptor as a tumor marker. The aim of this preclinical study was the evaluation
of FE@SUPPY as a PET-tracer for CRC using in vitro imaging and in vivo PET imaging.
First, affinity and selectivity of FE@SUPPY and its metabolites were determined,
proving the favorable binding profile of FE@SUPPY. The human adenocarcinoma cell
line HT-29 was characterized regarding its hA3AR expression and was subsequently
chosen as tumor graft. Promising results regarding the potential of FE@SUPPY as
a PET-tracer for CRC imaging were obtained by autoradiography as ≥2.3-fold higher
accumulation of FE@SUPPY was found in CRC tissue compared to adjacent healthy
colon tissue from the same patient. Nevertheless, first in vivo studies using
HT-29 xenografts showed insufficient tumor uptake due to (1) poor conservation
of target expression in xenografts and (2) unfavorable pharmacokinetics of FE@SUPPY
in mice. We therefore conclude that HT-29 xenografts are not adequate to visualize
hA3ARs using FE@SUPPY.
article_number: '1269830'
article_processing_charge: No
article_type: original
author:
- first_name: T.
full_name: Balber, T.
last_name: Balber
- first_name: Judit
full_name: Singer, Judit
id: 36432834-F248-11E8-B48F-1D18A9856A87
last_name: Singer
orcid: 0000-0002-8777-3502
- first_name: N.
full_name: Berroterán-Infante, N.
last_name: Berroterán-Infante
- first_name: M.
full_name: Dumanic, M.
last_name: Dumanic
- first_name: L.
full_name: Fetty, L.
last_name: Fetty
- first_name: J.
full_name: Fazekas-Singer, J.
last_name: Fazekas-Singer
orcid: 0000-0002-8777-3502
- first_name: C.
full_name: Vraka, C.
last_name: Vraka
- first_name: L.
full_name: Nics, L.
last_name: Nics
- first_name: M.
full_name: Bergmann, M.
last_name: Bergmann
- first_name: K.
full_name: Pallitsch, K.
last_name: Pallitsch
- first_name: H.
full_name: Spreitzer, H.
last_name: Spreitzer
- first_name: W.
full_name: Wadsak, W.
last_name: Wadsak
orcid: 0000-0003-4479-8053
- first_name: M.
full_name: Hacker, M.
last_name: Hacker
- first_name: E.
full_name: Jensen-Jarolim, E.
last_name: Jensen-Jarolim
- first_name: H.
full_name: Viernstein, H.
last_name: Viernstein
- first_name: M.
full_name: Mitterhauser, M.
last_name: Mitterhauser
orcid: 0000-0003-3173-5272
citation:
ama: 'Balber T, Singer J, Berroterán-Infante N, et al. Preclinical in vitro and
in vivo evaluation of [18F]FE@SUPPY for cancer PET imaging: Limitations of a xenograft
model for colorectal cancer. Contrast Media & Molecular Imaging. 2018;2018.
doi:10.1155/2018/1269830'
apa: 'Balber, T., Singer, J., Berroterán-Infante, N., Dumanic, M., Fetty, L., Fazekas-Singer,
J., … Mitterhauser, M. (2018). Preclinical in vitro and in vivo evaluation of
[18F]FE@SUPPY for cancer PET imaging: Limitations of a xenograft model for colorectal
cancer. Contrast Media & Molecular Imaging. Hindawi. https://doi.org/10.1155/2018/1269830'
chicago: 'Balber, T., Judit Singer, N. Berroterán-Infante, M. Dumanic, L. Fetty,
J. Fazekas-Singer, C. Vraka, et al. “Preclinical in Vitro and in Vivo Evaluation
of [18F]FE@SUPPY for Cancer PET Imaging: Limitations of a Xenograft Model for
Colorectal Cancer.” Contrast Media & Molecular Imaging. Hindawi, 2018.
https://doi.org/10.1155/2018/1269830.'
ieee: 'T. Balber et al., “Preclinical in vitro and in vivo evaluation of
[18F]FE@SUPPY for cancer PET imaging: Limitations of a xenograft model for colorectal
cancer,” Contrast Media & Molecular Imaging, vol. 2018. Hindawi, 2018.'
ista: 'Balber T, Singer J, Berroterán-Infante N, Dumanic M, Fetty L, Fazekas-Singer
J, Vraka C, Nics L, Bergmann M, Pallitsch K, Spreitzer H, Wadsak W, Hacker M,
Jensen-Jarolim E, Viernstein H, Mitterhauser M. 2018. Preclinical in vitro and
in vivo evaluation of [18F]FE@SUPPY for cancer PET imaging: Limitations of a xenograft
model for colorectal cancer. Contrast Media & Molecular Imaging. 2018, 1269830.'
mla: 'Balber, T., et al. “Preclinical in Vitro and in Vivo Evaluation of [18F]FE@SUPPY
for Cancer PET Imaging: Limitations of a Xenograft Model for Colorectal Cancer.”
Contrast Media & Molecular Imaging, vol. 2018, 1269830, Hindawi, 2018,
doi:10.1155/2018/1269830.'
short: T. Balber, J. Singer, N. Berroterán-Infante, M. Dumanic, L. Fetty, J. Fazekas-Singer,
C. Vraka, L. Nics, M. Bergmann, K. Pallitsch, H. Spreitzer, W. Wadsak, M. Hacker,
E. Jensen-Jarolim, H. Viernstein, M. Mitterhauser, Contrast Media & Molecular
Imaging 2018 (2018).
date_created: 2020-08-10T11:53:07Z
date_published: 2018-02-13T00:00:00Z
date_updated: 2021-01-12T08:17:38Z
day: '13'
doi: 10.1155/2018/1269830
extern: '1'
intvolume: ' 2018'
language:
- iso: eng
main_file_link:
- open_access: '1'
url: https://doi.org/10.1155/2018/1269830
month: '02'
oa: 1
oa_version: Published Version
publication: Contrast Media & Molecular Imaging
publication_identifier:
issn:
- 1555-4309
- 1555-4317
publication_status: published
publisher: Hindawi
quality_controlled: '1'
status: public
title: 'Preclinical in vitro and in vivo evaluation of [18F]FE@SUPPY for cancer PET
imaging: Limitations of a xenograft model for colorectal cancer'
type: journal_article
user_id: 2DF688A6-F248-11E8-B48F-1D18A9856A87
volume: 2018
year: '2018'
...
---
_id: '8274'
abstract:
- lang: eng
text: 'Background/Aim: Our aim was to investigate the crosstalk between tumor and
immune cells (M2 macrophages) and its effects on cyclo-oxygenase-2 (COX2) regulation
in canine mammary tumors (CMT). Materials and Methods: Sh1b CMT cells and human
BT474 mammary or HT29 colon cancer cells were co-cultured with canine peripheral
blood mononuclear cells (PBMCs) or with macrophage-like differentiated THP1 monocytes
(dTHP1). Intracellular COX2 expression by PBMCs, dTHP1 and cancer cells was evaluated
by flow cytometry. Results: Co-culturing of Sh1b and canine PBMCs induced COX2
overexpression in CMT cells. In turn, COX2 expression by PBMCs, mostly CD68+ macrophages,
was attenuated by co-culture with Sh1b (p=0.0001). In accordance, co-culture with
dTHP1 prompted intracellular production of COX2 in both Sh1b CMT cells and HT29
human colon cancer cells and reduced production of COX2 in BT474 human mammary
cancer cells. The intracellular COX2 expression from dTHP1 decreased when treated
with conditioned medium from cultured Sh1b and HT29 cancer cells. Conclusion:
Bidirectional COX2 regulation between cancer and monocytes/macrophages might shape
a tolerogenic tumor microenvironment in CMT.'
article_processing_charge: No
article_type: original
author:
- first_name: Maria Isabel
full_name: Carvalho, Maria Isabel
last_name: Carvalho
- first_name: Rodolfo
full_name: Bianchini, Rodolfo
last_name: Bianchini
- first_name: Judit
full_name: Fazekas-Singer, Judit
id: 36432834-F248-11E8-B48F-1D18A9856A87
last_name: Fazekas-Singer
orcid: 0000-0002-8777-3502
- first_name: Ina
full_name: Herrmann, Ina
last_name: Herrmann
- first_name: Irene
full_name: Flickinger, Irene
last_name: Flickinger
- first_name: Johann G.
full_name: Thalhammer, Johann G.
last_name: Thalhammer
- first_name: Isabel
full_name: Pires, Isabel
last_name: Pires
- first_name: Erika
full_name: Jensen-Jarolim, Erika
last_name: Jensen-Jarolim
- first_name: Felisbina L.
full_name: Queiroga, Felisbina L.
last_name: Queiroga
citation:
ama: Carvalho MI, Bianchini R, Singer J, et al. Bidirectional regulation of COX-2
expression between cancer cells and macrophages. Anticancer Research. 2018;38(5):2811-2817.
doi:10.21873/anticanres.12525
apa: Carvalho, M. I., Bianchini, R., Singer, J., Herrmann, I., Flickinger, I., Thalhammer,
J. G., … Queiroga, F. L. (2018). Bidirectional regulation of COX-2 expression
between cancer cells and macrophages. Anticancer Research. International
Institute of Anticancer Research. https://doi.org/10.21873/anticanres.12525
chicago: Carvalho, Maria Isabel, Rodolfo Bianchini, Judit Singer, Ina Herrmann,
Irene Flickinger, Johann G. Thalhammer, Isabel Pires, Erika Jensen-Jarolim, and
Felisbina L. Queiroga. “Bidirectional Regulation of COX-2 Expression between Cancer
Cells and Macrophages.” Anticancer Research. International Institute of
Anticancer Research, 2018. https://doi.org/10.21873/anticanres.12525.
ieee: M. I. Carvalho et al., “Bidirectional regulation of COX-2 expression
between cancer cells and macrophages,” Anticancer Research, vol. 38, no.
5. International Institute of Anticancer Research, pp. 2811–2817, 2018.
ista: Carvalho MI, Bianchini R, Singer J, Herrmann I, Flickinger I, Thalhammer JG,
Pires I, Jensen-Jarolim E, Queiroga FL. 2018. Bidirectional regulation of COX-2
expression between cancer cells and macrophages. Anticancer Research. 38(5), 2811–2817.
mla: Carvalho, Maria Isabel, et al. “Bidirectional Regulation of COX-2 Expression
between Cancer Cells and Macrophages.” Anticancer Research, vol. 38, no.
5, International Institute of Anticancer Research, 2018, pp. 2811–17, doi:10.21873/anticanres.12525.
short: M.I. Carvalho, R. Bianchini, J. Singer, I. Herrmann, I. Flickinger, J.G.
Thalhammer, I. Pires, E. Jensen-Jarolim, F.L. Queiroga, Anticancer Research 38
(2018) 2811–2817.
date_created: 2020-08-17T07:13:55Z
date_published: 2018-05-01T00:00:00Z
date_updated: 2021-01-12T08:17:52Z
day: '01'
doi: 10.21873/anticanres.12525
extern: '1'
intvolume: ' 38'
issue: '5'
language:
- iso: eng
month: '05'
oa_version: None
page: 2811-2817
publication: Anticancer Research
publication_identifier:
eissn:
- 1791-7530
issn:
- 0250-7005
publication_status: published
publisher: International Institute of Anticancer Research
quality_controlled: '1'
status: public
title: Bidirectional regulation of COX-2 expression between cancer cells and macrophages
type: journal_article
user_id: 2DF688A6-F248-11E8-B48F-1D18A9856A87
volume: 38
year: '2018'
...
---
_id: '8235'
abstract:
- lang: eng
text: Due to large homology of human and canine EGFR, dogs suffering from spontaneous
EGFR+ cancer can be considered as ideal translational models. Thereby, novel immunotherapeutic
compounds can be developed for both human and veterinary patients. This study
describes the radiolabeling of a canine anti-EGFR IgG antibody (can225IgG) with
potential diagnostic and therapeutic value in comparative clinical settings. Can225IgG
was functionalized with DTPA for subsequent chelation with the radionuclide 99mTc.
Successful coupling of 10 DTPA molecules per antibody on average was proven by
significant mass increase in MALDI-TOF spectroscopy, gel electrophoresis and immunoblots.
Following functionalization and radiolabeling, 99mTc-DTPA-can225IgG fully retained
its binding capacity towards human and canine EGFR in flow cytometry, immuno-
and radioblots, and autoradiography. The affinity of radiolabeled can225IgG was
determined to KD 0.8 ±0.0031 nM in a real-time kinetics assay on canine carcinoma
cells by a competition binding technique. Stability tests of the radiolabeled
compound identified TRIS buffered saline as the ideal formulation for short-term
storage with 87.11 ±6.04% intact compound being still detected 60 minutes post
radiolabeling. High stability, specificity and EGFR binding affinity pinpoint
towards 99mTc-radiolabeled can225IgG antibody as an ideal lead compound for the
first proof-of-concept diagnostic and therapeutic applications in canine cancer
patients.
article_processing_charge: No
article_type: original
author:
- first_name: Judit
full_name: Fazekas-Singer, Judit
id: 36432834-F248-11E8-B48F-1D18A9856A87
last_name: Fazekas-Singer
orcid: 0000-0002-8777-3502
- first_name: Neydher
full_name: Berroterán-Infante, Neydher
last_name: Berroterán-Infante
- first_name: Christina
full_name: Rami-Mark, Christina
last_name: Rami-Mark
- first_name: Monika
full_name: Dumanic, Monika
last_name: Dumanic
- first_name: Miroslawa
full_name: Matz, Miroslawa
last_name: Matz
- first_name: Michael
full_name: Willmann, Michael
last_name: Willmann
- first_name: Fritz
full_name: Andreae, Fritz
last_name: Andreae
- first_name: Josef
full_name: Singer, Josef
last_name: Singer
- first_name: Wolfgang
full_name: Wadsak, Wolfgang
last_name: Wadsak
- first_name: Markus
full_name: Mitterhauser, Markus
last_name: Mitterhauser
- first_name: Erika
full_name: Jensen-Jarolim, Erika
last_name: Jensen-Jarolim
citation:
ama: Singer J, Berroterán-Infante N, Rami-Mark C, et al. Development of a radiolabeled
caninized anti-EGFR antibody for comparative oncology trials. Oncotarget.
2017;8:83128-83141. doi:10.18632/oncotarget.20914
apa: Singer, J., Berroterán-Infante, N., Rami-Mark, C., Dumanic, M., Matz, M., Willmann,
M., … Jensen-Jarolim, E. (2017). Development of a radiolabeled caninized anti-EGFR
antibody for comparative oncology trials. Oncotarget. Impact Journals.
https://doi.org/10.18632/oncotarget.20914
chicago: Singer, Judit, Neydher Berroterán-Infante, Christina Rami-Mark, Monika
Dumanic, Miroslawa Matz, Michael Willmann, Fritz Andreae, et al. “Development
of a Radiolabeled Caninized Anti-EGFR Antibody for Comparative Oncology Trials.”
Oncotarget. Impact Journals, 2017. https://doi.org/10.18632/oncotarget.20914.
ieee: J. Singer et al., “Development of a radiolabeled caninized anti-EGFR
antibody for comparative oncology trials,” Oncotarget, vol. 8. Impact Journals,
pp. 83128–83141, 2017.
ista: Singer J, Berroterán-Infante N, Rami-Mark C, Dumanic M, Matz M, Willmann M,
Andreae F, Singer J, Wadsak W, Mitterhauser M, Jensen-Jarolim E. 2017. Development
of a radiolabeled caninized anti-EGFR antibody for comparative oncology trials.
Oncotarget. 8, 83128–83141.
mla: Singer, Judit, et al. “Development of a Radiolabeled Caninized Anti-EGFR Antibody
for Comparative Oncology Trials.” Oncotarget, vol. 8, Impact Journals,
2017, pp. 83128–41, doi:10.18632/oncotarget.20914.
short: J. Singer, N. Berroterán-Infante, C. Rami-Mark, M. Dumanic, M. Matz, M. Willmann,
F. Andreae, J. Singer, W. Wadsak, M. Mitterhauser, E. Jensen-Jarolim, Oncotarget
8 (2017) 83128–83141.
date_created: 2020-08-10T11:53:18Z
date_published: 2017-09-15T00:00:00Z
date_updated: 2021-01-12T08:17:39Z
day: '15'
doi: 10.18632/oncotarget.20914
extern: '1'
intvolume: ' 8'
language:
- iso: eng
main_file_link:
- open_access: '1'
url: https://doi.org/10.18632/oncotarget.20914
month: '09'
oa: 1
oa_version: Published Version
page: 83128-83141
publication: Oncotarget
publication_identifier:
issn:
- 1949-2553
publication_status: published
publisher: Impact Journals
quality_controlled: '1'
status: public
title: Development of a radiolabeled caninized anti-EGFR antibody for comparative
oncology trials
type: journal_article
user_id: 2DF688A6-F248-11E8-B48F-1D18A9856A87
volume: 8
year: '2017'
...
---
_id: '8236'
abstract:
- lang: eng
text: Th2 immunity and allergic immune surveillance play critical roles in host
responses to pathogens, parasites and allergens. Numerous studies have reported
significant links between Th2 responses and cancer, including insights into the
functions of IgE antibodies and associated effector cells in both antitumour immune
surveillance and therapy. The interdisciplinary field of AllergoOncology was given
Task Force status by the European Academy of Allergy and Clinical Immunology in
2014. Affiliated expert groups focus on the interface between allergic responses
and cancer, applied to immune surveillance, immunomodulation and the functions
of IgE‐mediated immune responses against cancer, to derive novel insights into
more effective treatments. Coincident with rapid expansion in clinical application
of cancer immunotherapies, here we review the current state‐of‐the‐art and future
translational opportunities, as well as challenges in this relatively new field.
Recent developments include improved understanding of Th2 antibodies, intratumoral
innate allergy effector cells and mediators, IgE‐mediated tumour antigen cross‐presentation
by dendritic cells, as well as immunotherapeutic strategies such as vaccines and
recombinant antibodies, and finally, the management of allergy in daily clinical
oncology. Shedding light on the crosstalk between allergic response and cancer
is paving the way for new avenues of treatment.
article_processing_charge: No
article_type: original
author:
- first_name: E.
full_name: Jensen-Jarolim, E.
last_name: Jensen-Jarolim
orcid: 0000-0003-4019-5765
- first_name: H. J.
full_name: Bax, H. J.
last_name: Bax
- first_name: R.
full_name: Bianchini, R.
last_name: Bianchini
- first_name: M.
full_name: Capron, M.
last_name: Capron
- first_name: C.
full_name: Corrigan, C.
last_name: Corrigan
- first_name: M.
full_name: Castells, M.
last_name: Castells
- first_name: D.
full_name: Dombrowicz, D.
last_name: Dombrowicz
- first_name: T. R.
full_name: Daniels-Wells, T. R.
last_name: Daniels-Wells
- first_name: Judit
full_name: Fazekas, Judit
id: 36432834-F248-11E8-B48F-1D18A9856A87
last_name: Fazekas
orcid: 0000-0002-8777-3502
- first_name: E.
full_name: Fiebiger, E.
last_name: Fiebiger
- first_name: S.
full_name: Gatault, S.
last_name: Gatault
- first_name: H. J.
full_name: Gould, H. J.
last_name: Gould
- first_name: J.
full_name: Janda, J.
last_name: Janda
- first_name: D. H.
full_name: Josephs, D. H.
last_name: Josephs
- first_name: P.
full_name: Karagiannis, P.
last_name: Karagiannis
- first_name: F.
full_name: Levi-Schaffer, F.
last_name: Levi-Schaffer
- first_name: A.
full_name: Meshcheryakova, A.
last_name: Meshcheryakova
- first_name: D.
full_name: Mechtcheriakova, D.
last_name: Mechtcheriakova
- first_name: Y.
full_name: Mekori, Y.
last_name: Mekori
- first_name: F.
full_name: Mungenast, F.
last_name: Mungenast
- first_name: E. A.
full_name: Nigro, E. A.
last_name: Nigro
- first_name: M. L.
full_name: Penichet, M. L.
last_name: Penichet
- first_name: F.
full_name: Redegeld, F.
last_name: Redegeld
- first_name: L.
full_name: Saul, L.
last_name: Saul
- first_name: J.
full_name: Singer, J.
last_name: Singer
- first_name: J. F.
full_name: Spicer, J. F.
last_name: Spicer
- first_name: A. G.
full_name: Siccardi, A. G.
last_name: Siccardi
- first_name: E.
full_name: Spillner, E.
last_name: Spillner
- first_name: M. C.
full_name: Turner, M. C.
last_name: Turner
- first_name: E.
full_name: Untersmayr, E.
last_name: Untersmayr
- first_name: L.
full_name: Vangelista, L.
last_name: Vangelista
- first_name: S. N.
full_name: Karagiannis, S. N.
last_name: Karagiannis
citation:
ama: 'Jensen-Jarolim E, Bax HJ, Bianchini R, et al. AllergoOncology - the impact
of allergy in oncology: EAACI position paper. Allergy. 2017;72(6):866-887.
doi:10.1111/all.13119'
apa: 'Jensen-Jarolim, E., Bax, H. J., Bianchini, R., Capron, M., Corrigan, C., Castells,
M., … Karagiannis, S. N. (2017). AllergoOncology - the impact of allergy in oncology:
EAACI position paper. Allergy. Wiley. https://doi.org/10.1111/all.13119'
chicago: 'Jensen-Jarolim, E., H. J. Bax, R. Bianchini, M. Capron, C. Corrigan, M.
Castells, D. Dombrowicz, et al. “AllergoOncology - the Impact of Allergy in Oncology:
EAACI Position Paper.” Allergy. Wiley, 2017. https://doi.org/10.1111/all.13119.'
ieee: 'E. Jensen-Jarolim et al., “AllergoOncology - the impact of allergy
in oncology: EAACI position paper,” Allergy, vol. 72, no. 6. Wiley, pp.
866–887, 2017.'
ista: 'Jensen-Jarolim E, Bax HJ, Bianchini R, Capron M, Corrigan C, Castells M,
Dombrowicz D, Daniels-Wells TR, Singer J, Fiebiger E, Gatault S, Gould HJ, Janda
J, Josephs DH, Karagiannis P, Levi-Schaffer F, Meshcheryakova A, Mechtcheriakova
D, Mekori Y, Mungenast F, Nigro EA, Penichet ML, Redegeld F, Saul L, Singer J,
Spicer JF, Siccardi AG, Spillner E, Turner MC, Untersmayr E, Vangelista L, Karagiannis
SN. 2017. AllergoOncology - the impact of allergy in oncology: EAACI position
paper. Allergy. 72(6), 866–887.'
mla: 'Jensen-Jarolim, E., et al. “AllergoOncology - the Impact of Allergy in Oncology:
EAACI Position Paper.” Allergy, vol. 72, no. 6, Wiley, 2017, pp. 866–87,
doi:10.1111/all.13119.'
short: E. Jensen-Jarolim, H.J. Bax, R. Bianchini, M. Capron, C. Corrigan, M. Castells,
D. Dombrowicz, T.R. Daniels-Wells, J. Singer, E. Fiebiger, S. Gatault, H.J. Gould,
J. Janda, D.H. Josephs, P. Karagiannis, F. Levi-Schaffer, A. Meshcheryakova, D.
Mechtcheriakova, Y. Mekori, F. Mungenast, E.A. Nigro, M.L. Penichet, F. Redegeld,
L. Saul, J. Singer, J.F. Spicer, A.G. Siccardi, E. Spillner, M.C. Turner, E. Untersmayr,
L. Vangelista, S.N. Karagiannis, Allergy 72 (2017) 866–887.
date_created: 2020-08-10T11:53:26Z
date_published: 2017-06-01T00:00:00Z
date_updated: 2021-01-12T08:17:39Z
day: '01'
doi: 10.1111/all.13119
extern: '1'
intvolume: ' 72'
issue: '6'
language:
- iso: eng
main_file_link:
- open_access: '1'
url: https://doi.org/10.1111/all.13119
month: '06'
oa: 1
oa_version: Published Version
page: 866-887
publication: Allergy
publication_identifier:
issn:
- 0105-4538
publication_status: published
publisher: Wiley
quality_controlled: '1'
status: public
title: 'AllergoOncology - the impact of allergy in oncology: EAACI position paper'
type: journal_article
user_id: 2DF688A6-F248-11E8-B48F-1D18A9856A87
volume: 72
year: '2017'
...
---
_id: '8237'
abstract:
- lang: eng
text: Monoclonal antibodies find broad application as therapy for various types
of cancer by employing multiple mechanisms of action against tumors. Manipulating
the Fc-mediated functions of antibodies that engage immune effector cells, such
as NK cells, represents a strategy to influence effector cell activation and to
enhance antibody potency and potentially efficacy. We developed a novel approach
to generate and ascertain the functional attributes of Fc mutant monoclonal antibodies.
This entailed coupling single expression vector (pVitro1) antibody cloning, using
polymerase incomplete primer extension (PIPE) polymerase chain reaction, together
with simultaneous Fc region point mutagenesis and high yield transient expression
in human mammalian cells. Employing this, we engineered wild type, low (N297Q,
NQ), and high (S239D/I332E, DE) FcR-binding Fc mutant monoclonal antibody panels
recognizing two cancer antigens, HER2/neu and chondroitin sulfate proteoglycan
4. Antibodies were generated with universal mutagenic primers applicable to any
IgG1 pVitro1 constructs, with high mutagenesis and transfection efficiency, in
small culture volumes, at high yields and within 12 days from design to purified
material. Antibody variants conserved their Fab-mediated recognition of target
antigens and their direct anti-proliferative effects against cancer cells. Fc
mutations had a significant impact on antibody interactions with Fc receptors
(FcRs) on human NK cells, and consequently on the potency of NK cell activation,
quantified by immune complex-mediated calcium mobilization and by antibody-dependent
cellular cytotoxicity (ADCC) of tumor cells. This strategy for manipulation and
testing of Fc region engagement with cognate FcRs can facilitate the design of
antibodies with defined effector functions and potentially enhanced efficacy against
tumor cells.
article_number: '1112'
article_processing_charge: No
article_type: original
author:
- first_name: Kristina M.
full_name: Ilieva, Kristina M.
last_name: Ilieva
- first_name: Judit
full_name: Fazekas-Singer, Judit
id: 36432834-F248-11E8-B48F-1D18A9856A87
last_name: Fazekas-Singer
orcid: 0000-0002-8777-3502
- first_name: Daniela Y.
full_name: Achkova, Daniela Y.
last_name: Achkova
- first_name: Tihomir S.
full_name: Dodev, Tihomir S.
last_name: Dodev
- first_name: Silvia
full_name: Mele, Silvia
last_name: Mele
- first_name: Silvia
full_name: Crescioli, Silvia
last_name: Crescioli
- first_name: Heather J.
full_name: Bax, Heather J.
last_name: Bax
- first_name: Anthony
full_name: Cheung, Anthony
last_name: Cheung
- first_name: Panagiotis
full_name: Karagiannis, Panagiotis
last_name: Karagiannis
- first_name: Isabel
full_name: Correa, Isabel
last_name: Correa
- first_name: Mariangela
full_name: Figini, Mariangela
last_name: Figini
- first_name: Rebecca
full_name: Marlow, Rebecca
last_name: Marlow
- first_name: Debra H.
full_name: Josephs, Debra H.
last_name: Josephs
- first_name: Andrew J.
full_name: Beavil, Andrew J.
last_name: Beavil
- first_name: John
full_name: Maher, John
last_name: Maher
- first_name: James F.
full_name: Spicer, James F.
last_name: Spicer
- first_name: Erika
full_name: Jensen-Jarolim, Erika
last_name: Jensen-Jarolim
- first_name: Andrew N.
full_name: Tutt, Andrew N.
last_name: Tutt
- first_name: Sophia N.
full_name: Karagiannis, Sophia N.
last_name: Karagiannis
citation:
ama: Ilieva KM, Singer J, Achkova DY, et al. Functionally active Fc mutant antibodies
recognizing cancer antigens generated rapidly at high yields. Frontiers in
Immunology. 2017;8. doi:10.3389/fimmu.2017.01112
apa: Ilieva, K. M., Singer, J., Achkova, D. Y., Dodev, T. S., Mele, S., Crescioli,
S., … Karagiannis, S. N. (2017). Functionally active Fc mutant antibodies recognizing
cancer antigens generated rapidly at high yields. Frontiers in Immunology.
Frontiers. https://doi.org/10.3389/fimmu.2017.01112
chicago: Ilieva, Kristina M., Judit Singer, Daniela Y. Achkova, Tihomir S. Dodev,
Silvia Mele, Silvia Crescioli, Heather J. Bax, et al. “Functionally Active Fc
Mutant Antibodies Recognizing Cancer Antigens Generated Rapidly at High Yields.”
Frontiers in Immunology. Frontiers, 2017. https://doi.org/10.3389/fimmu.2017.01112.
ieee: K. M. Ilieva et al., “Functionally active Fc mutant antibodies recognizing
cancer antigens generated rapidly at high yields,” Frontiers in Immunology,
vol. 8. Frontiers, 2017.
ista: Ilieva KM, Singer J, Achkova DY, Dodev TS, Mele S, Crescioli S, Bax HJ, Cheung
A, Karagiannis P, Correa I, Figini M, Marlow R, Josephs DH, Beavil AJ, Maher J,
Spicer JF, Jensen-Jarolim E, Tutt AN, Karagiannis SN. 2017. Functionally active
Fc mutant antibodies recognizing cancer antigens generated rapidly at high yields.
Frontiers in Immunology. 8, 1112.
mla: Ilieva, Kristina M., et al. “Functionally Active Fc Mutant Antibodies Recognizing
Cancer Antigens Generated Rapidly at High Yields.” Frontiers in Immunology,
vol. 8, 1112, Frontiers, 2017, doi:10.3389/fimmu.2017.01112.
short: K.M. Ilieva, J. Singer, D.Y. Achkova, T.S. Dodev, S. Mele, S. Crescioli,
H.J. Bax, A. Cheung, P. Karagiannis, I. Correa, M. Figini, R. Marlow, D.H. Josephs,
A.J. Beavil, J. Maher, J.F. Spicer, E. Jensen-Jarolim, A.N. Tutt, S.N. Karagiannis,
Frontiers in Immunology 8 (2017).
date_created: 2020-08-10T11:53:32Z
date_published: 2017-09-11T00:00:00Z
date_updated: 2021-01-12T08:17:39Z
day: '11'
doi: 10.3389/fimmu.2017.01112
extern: '1'
intvolume: ' 8'
language:
- iso: eng
main_file_link:
- open_access: '1'
url: https://doi.org/10.3389/fimmu.2017.01112
month: '09'
oa: 1
oa_version: Published Version
publication: Frontiers in Immunology
publication_identifier:
issn:
- 1664-3224
publication_status: published
publisher: Frontiers
quality_controlled: '1'
status: public
title: Functionally active Fc mutant antibodies recognizing cancer antigens generated
rapidly at high yields
type: journal_article
user_id: 2DF688A6-F248-11E8-B48F-1D18A9856A87
volume: 8
year: '2017'
...
---
_id: '8239'
abstract:
- lang: eng
text: Acrolein, a highly reactive unsaturated aldehyde, is generated in large amounts
during smoking and is best known for its genotoxic capacity. Here, we aimed to
assess whether acrolein at concentrations relevant for smokers may also exert
immunomodulatory effects that could be relevant in allergy or cancer. In a BALB/c
allergy model repeated nasal exposure to acrolein abrogated allergen-specific
antibody and cytokine formation, and led to a relative accumulation of regulatory
T cells in the lungs. Only the acrolein-treated mice were protected from bronchial
hyperreactivity as well as from anaphylactic reactions upon challenge with the
specific allergen. Moreover, grafted D2F2 tumor cells grew faster and intratumoral
Foxp3+ cell accumulation was observed in these mice compared to sham-treated controls.
Results from reporter cell lines suggested that acrolein acts via the aryl-hydrocarbon
receptor which could be inhibited by resveratrol and 3′-methoxy-4′-nitroflavone
Acrolein- stimulation of human PBMCs increased Foxp3+ expression by T cells which
could be antagonized by resveratrol. Our mouse and human data thus revealed that
acrolein exerts systemic immunosuppression by promoting Foxp3+ regulatory cells.
This provides a novel explanation why smokers have a lower allergy, but higher
cancer risk.
article_number: '45067'
article_processing_charge: No
article_type: original
author:
- first_name: Franziska
full_name: Roth-Walter, Franziska
last_name: Roth-Walter
- first_name: Cornelia
full_name: Bergmayr, Cornelia
last_name: Bergmayr
- first_name: Sarah
full_name: Meitz, Sarah
last_name: Meitz
- first_name: Stefan
full_name: Buchleitner, Stefan
last_name: Buchleitner
- first_name: Caroline
full_name: Stremnitzer, Caroline
last_name: Stremnitzer
- first_name: Judit
full_name: Fazekas, Judit
id: 36432834-F248-11E8-B48F-1D18A9856A87
last_name: Fazekas
orcid: 0000-0002-8777-3502
- first_name: Anna
full_name: Moskovskich, Anna
last_name: Moskovskich
- first_name: Mario A.
full_name: Müller, Mario A.
last_name: Müller
- first_name: Georg A.
full_name: Roth, Georg A.
last_name: Roth
- first_name: Krisztina
full_name: Manzano-Szalai, Krisztina
last_name: Manzano-Szalai
- first_name: Zdenek
full_name: Dvorak, Zdenek
last_name: Dvorak
- first_name: Alina
full_name: Neunkirchner, Alina
last_name: Neunkirchner
- first_name: Erika
full_name: Jensen-Jarolim, Erika
last_name: Jensen-Jarolim
citation:
ama: 'Roth-Walter F, Bergmayr C, Meitz S, et al. Janus-faced Acrolein prevents allergy
but accelerates tumor growth by promoting immunoregulatory Foxp3+ cells: Mouse
model for passive respiratory exposure. Scientific Reports. 2017;7. doi:10.1038/srep45067'
apa: 'Roth-Walter, F., Bergmayr, C., Meitz, S., Buchleitner, S., Stremnitzer, C.,
Singer, J., … Jensen-Jarolim, E. (2017). Janus-faced Acrolein prevents allergy
but accelerates tumor growth by promoting immunoregulatory Foxp3+ cells: Mouse
model for passive respiratory exposure. Scientific Reports. Springer Nature.
https://doi.org/10.1038/srep45067'
chicago: 'Roth-Walter, Franziska, Cornelia Bergmayr, Sarah Meitz, Stefan Buchleitner,
Caroline Stremnitzer, Judit Singer, Anna Moskovskich, et al. “Janus-Faced Acrolein
Prevents Allergy but Accelerates Tumor Growth by Promoting Immunoregulatory Foxp3+
Cells: Mouse Model for Passive Respiratory Exposure.” Scientific Reports.
Springer Nature, 2017. https://doi.org/10.1038/srep45067.'
ieee: 'F. Roth-Walter et al., “Janus-faced Acrolein prevents allergy but
accelerates tumor growth by promoting immunoregulatory Foxp3+ cells: Mouse model
for passive respiratory exposure,” Scientific Reports, vol. 7. Springer
Nature, 2017.'
ista: 'Roth-Walter F, Bergmayr C, Meitz S, Buchleitner S, Stremnitzer C, Singer
J, Moskovskich A, Müller MA, Roth GA, Manzano-Szalai K, Dvorak Z, Neunkirchner
A, Jensen-Jarolim E. 2017. Janus-faced Acrolein prevents allergy but accelerates
tumor growth by promoting immunoregulatory Foxp3+ cells: Mouse model for passive
respiratory exposure. Scientific Reports. 7, 45067.'
mla: 'Roth-Walter, Franziska, et al. “Janus-Faced Acrolein Prevents Allergy but
Accelerates Tumor Growth by Promoting Immunoregulatory Foxp3+ Cells: Mouse Model
for Passive Respiratory Exposure.” Scientific Reports, vol. 7, 45067, Springer
Nature, 2017, doi:10.1038/srep45067.'
short: F. Roth-Walter, C. Bergmayr, S. Meitz, S. Buchleitner, C. Stremnitzer, J.
Singer, A. Moskovskich, M.A. Müller, G.A. Roth, K. Manzano-Szalai, Z. Dvorak,
A. Neunkirchner, E. Jensen-Jarolim, Scientific Reports 7 (2017).
date_created: 2020-08-10T11:53:46Z
date_published: 2017-03-23T00:00:00Z
date_updated: 2021-01-12T08:17:40Z
day: '23'
doi: 10.1038/srep45067
extern: '1'
intvolume: ' 7'
language:
- iso: eng
main_file_link:
- open_access: '1'
url: https://doi.org/10.1038/srep45067
month: '03'
oa: 1
oa_version: Published Version
publication: Scientific Reports
publication_identifier:
issn:
- 2045-2322
publication_status: published
publisher: Springer Nature
quality_controlled: '1'
status: public
title: 'Janus-faced Acrolein prevents allergy but accelerates tumor growth by promoting
immunoregulatory Foxp3+ cells: Mouse model for passive respiratory exposure'
type: journal_article
user_id: 2DF688A6-F248-11E8-B48F-1D18A9856A87
volume: 7
year: '2017'
...
---
_id: '8240'
abstract:
- lang: eng
text: "Background/Aim: Cancer cell lines are indispensible surrogate models in cancer
research, as they can be used off-the-shelf, expanded to the desired extent, easily
modified and exchanged between research groups for affirmation, reproduction or
follow-up experiments.\r\nAs malignant cells are prone to genomic instability,
phenotypical changes may occur after certain passages in culture. Thus, cell lines
have to be regularly authenticated to ensure data quality. In between experiments
these cell lines are often stored in liquid nitrogen for extended time periods.\r\nAlthough
freezing of cells is a necessary evil, little research is performed on how long-term
storage affects cancer cell lines. Therefore, this study investigated the effects
of a 28-year long liquid nitrogen storage period on BT474 cells with regard to
phenotypical changes, differences in cell-surface receptor expression as well
as cytokine and gene expressional variations.\r\nMethods: Two batches of BT474
cells, one frozen in 1986, the other directly purchased from ATCC were investigated
by light microscopy, cell growth analysis, flow cytometry and cytokine as well
as whole-transcriptome expression profiling.\r\nResults: The cell lines were morphologically
indifferent and showed similar growth rates and similar cell-surface receptor
expression. Transcriptome analysis revealed significant differences in only 26
of 40,716 investigated RefSeq transcripts with 4 of them being up-regulated and
22 down-regulated.\r\nConclusion: This study demonstrates that even after very
long periods of storage in liquid nitrogen, cancer cell lines display only minimal
changes in their gene expression profiles. However, also such minor changes should
be carefully assessed before continuation of experiments, especially if phenotypic
alterations can be additionally observed."
article_processing_charge: No
article_type: original
author:
- first_name: Judit
full_name: Fazekas, Judit
id: 36432834-F248-11E8-B48F-1D18A9856A87
last_name: Fazekas
orcid: 0000-0002-8777-3502
- first_name: Thomas W.
full_name: Grunt, Thomas W.
last_name: Grunt
- first_name: Erika
full_name: Jensen-Jarolim, Erika
last_name: Jensen-Jarolim
- first_name: Josef
full_name: Singer, Josef
last_name: Singer
citation:
ama: Singer J, Grunt TW, Jensen-Jarolim E, Singer J. Long term storage in liquid
nitrogen leads to only minor phenotypic and gene expression changes in the mammary
carcinoma model cell line BT474. Oncotarget. 2017;8:35076-35087. doi:10.18632/oncotarget.16623
apa: Singer, J., Grunt, T. W., Jensen-Jarolim, E., & Singer, J. (2017). Long
term storage in liquid nitrogen leads to only minor phenotypic and gene expression
changes in the mammary carcinoma model cell line BT474. Oncotarget. Impact
Journals. https://doi.org/10.18632/oncotarget.16623
chicago: Singer, Judit, Thomas W. Grunt, Erika Jensen-Jarolim, and Josef Singer.
“Long Term Storage in Liquid Nitrogen Leads to Only Minor Phenotypic and Gene
Expression Changes in the Mammary Carcinoma Model Cell Line BT474.” Oncotarget.
Impact Journals, 2017. https://doi.org/10.18632/oncotarget.16623.
ieee: J. Singer, T. W. Grunt, E. Jensen-Jarolim, and J. Singer, “Long term storage
in liquid nitrogen leads to only minor phenotypic and gene expression changes
in the mammary carcinoma model cell line BT474,” Oncotarget, vol. 8. Impact
Journals, pp. 35076–35087, 2017.
ista: Singer J, Grunt TW, Jensen-Jarolim E, Singer J. 2017. Long term storage in
liquid nitrogen leads to only minor phenotypic and gene expression changes in
the mammary carcinoma model cell line BT474. Oncotarget. 8, 35076–35087.
mla: Singer, Judit, et al. “Long Term Storage in Liquid Nitrogen Leads to Only Minor
Phenotypic and Gene Expression Changes in the Mammary Carcinoma Model Cell Line
BT474.” Oncotarget, vol. 8, Impact Journals, 2017, pp. 35076–87, doi:10.18632/oncotarget.16623.
short: J. Singer, T.W. Grunt, E. Jensen-Jarolim, J. Singer, Oncotarget 8 (2017)
35076–35087.
date_created: 2020-08-10T11:53:53Z
date_published: 2017-03-28T00:00:00Z
date_updated: 2021-01-12T08:17:41Z
day: '28'
doi: 10.18632/oncotarget.16623
extern: '1'
intvolume: ' 8'
language:
- iso: eng
main_file_link:
- open_access: '1'
url: https://doi.org/10.18632/oncotarget.16623
month: '03'
oa: 1
oa_version: Published Version
page: 35076-35087
publication: Oncotarget
publication_identifier:
issn:
- 1949-2553
publication_status: published
publisher: Impact Journals
quality_controlled: '1'
status: public
title: Long term storage in liquid nitrogen leads to only minor phenotypic and gene
expression changes in the mammary carcinoma model cell line BT474
type: journal_article
user_id: 2DF688A6-F248-11E8-B48F-1D18A9856A87
volume: 8
year: '2017'
...
---
_id: '8241'
abstract:
- lang: eng
text: 'Background: Anticancer vaccines could represent a valuable complementary
strategy to established therapies, especially in settings of early stage and minimal
residual disease. HER-2 is an important target for immunotherapy and addressed
by the monoclonal antibody trastuzumab. We have previously generated HER-2 mimotope
peptides from phage display libraries. The synthesized peptides were coupled to
carriers and applied for epitope-specific induction of trastuzumab-like IgG. For
simplification and to avoid methodological limitations of synthesis and coupling
chemistry, we herewith present a novel and optimized approach by using adeno-associated
viruses (AAV) as effective and high-density mimotope-display system, which can
be directly used for vaccination. Methods: An AAV capsid display library was constructed
by genetically incorporating random peptides in a plasmid encoding the wild-type
AAV2 capsid protein. AAV clones, expressing peptides specifically reactive to
trastuzumab, were employed to immunize BALB/c mice. Antibody titers against human
HER-2 were determined, and the isotype composition and functional properties of
these were tested. Finally, prophylactically immunized mice were challenged with
human HER-2 transfected mouse D2F2/E2 cells. Results: HER-2 mimotope AAV-vaccines
induced antibodies specific to human HER-2. Two clones were selected for immunization
of mice, which were subsequently grafted D2F2/E2 cells. Both mimotope AAV clones
delayed the growth of tumors significantly, as compared to controls. Conclusion:
In this study, a novel mimotope AAV-based platform was created allowing the isolation
of mimotopes, which can be directly used as anticancer vaccines. The example of
trastuzumab AAV-mimotopes demonstrates that this vaccine strategy could help to
establish active immunotherapy for breast-cancer patients.'
article_number: e1171446
article_processing_charge: No
article_type: original
author:
- first_name: Josef
full_name: Singer, Josef
last_name: Singer
- first_name: Krisztina
full_name: Manzano-Szalai, Krisztina
last_name: Manzano-Szalai
- first_name: Judit
full_name: Fazekas, Judit
id: 36432834-F248-11E8-B48F-1D18A9856A87
last_name: Fazekas
orcid: 0000-0002-8777-3502
- first_name: Kathrin
full_name: Thell, Kathrin
last_name: Thell
- first_name: Anna
full_name: Bentley-Lukschal, Anna
last_name: Bentley-Lukschal
- first_name: Caroline
full_name: Stremnitzer, Caroline
last_name: Stremnitzer
- first_name: Franziska
full_name: Roth-Walter, Franziska
last_name: Roth-Walter
- first_name: Margit
full_name: Weghofer, Margit
last_name: Weghofer
- first_name: Mirko
full_name: Ritter, Mirko
last_name: Ritter
- first_name: Kerstin
full_name: Pino Tossi, Kerstin
last_name: Pino Tossi
- first_name: Markus
full_name: Hörer, Markus
last_name: Hörer
- first_name: Uwe
full_name: Michaelis, Uwe
last_name: Michaelis
- first_name: Erika
full_name: Jensen-Jarolim, Erika
last_name: Jensen-Jarolim
citation:
ama: Singer J, Manzano-Szalai K, Singer J, et al. Proof of concept study with an
HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform.
OncoImmunology. 2016;5(7). doi:10.1080/2162402x.2016.1171446
apa: Singer, J., Manzano-Szalai, K., Singer, J., Thell, K., Bentley-Lukschal, A.,
Stremnitzer, C., … Jensen-Jarolim, E. (2016). Proof of concept study with an HER-2
mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform.
OncoImmunology. Taylor & Francis. https://doi.org/10.1080/2162402x.2016.1171446
chicago: Singer, Josef, Krisztina Manzano-Szalai, Judit Singer, Kathrin Thell, Anna
Bentley-Lukschal, Caroline Stremnitzer, Franziska Roth-Walter, et al. “Proof of
Concept Study with an HER-2 Mimotope Anticancer Vaccine Deduced from a Novel AAV-Mimotope
Library Platform.” OncoImmunology. Taylor & Francis, 2016. https://doi.org/10.1080/2162402x.2016.1171446.
ieee: J. Singer et al., “Proof of concept study with an HER-2 mimotope anticancer
vaccine deduced from a novel AAV-mimotope library platform,” OncoImmunology,
vol. 5, no. 7. Taylor & Francis, 2016.
ista: Singer J, Manzano-Szalai K, Singer J, Thell K, Bentley-Lukschal A, Stremnitzer
C, Roth-Walter F, Weghofer M, Ritter M, Pino Tossi K, Hörer M, Michaelis U, Jensen-Jarolim
E. 2016. Proof of concept study with an HER-2 mimotope anticancer vaccine deduced
from a novel AAV-mimotope library platform. OncoImmunology. 5(7), e1171446.
mla: Singer, Josef, et al. “Proof of Concept Study with an HER-2 Mimotope Anticancer
Vaccine Deduced from a Novel AAV-Mimotope Library Platform.” OncoImmunology,
vol. 5, no. 7, e1171446, Taylor & Francis, 2016, doi:10.1080/2162402x.2016.1171446.
short: J. Singer, K. Manzano-Szalai, J. Singer, K. Thell, A. Bentley-Lukschal, C.
Stremnitzer, F. Roth-Walter, M. Weghofer, M. Ritter, K. Pino Tossi, M. Hörer,
U. Michaelis, E. Jensen-Jarolim, OncoImmunology 5 (2016).
date_created: 2020-08-10T11:54:03Z
date_published: 2016-06-30T00:00:00Z
date_updated: 2021-01-12T08:17:41Z
day: '30'
doi: 10.1080/2162402x.2016.1171446
extern: '1'
intvolume: ' 5'
issue: '7'
language:
- iso: eng
main_file_link:
- open_access: '1'
url: https://doi.org/10.1080/2162402X.2016.1171446
month: '06'
oa: 1
oa_version: Published Version
publication: OncoImmunology
publication_identifier:
issn:
- 2162-402X
publication_status: published
publisher: Taylor & Francis
quality_controlled: '1'
status: public
title: Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from
a novel AAV-mimotope library platform
type: journal_article
user_id: 2DF688A6-F248-11E8-B48F-1D18A9856A87
volume: 5
year: '2016'
...
---
_id: '8242'
article_number: AB101
article_processing_charge: No
article_type: original
author:
- first_name: Lukas
full_name: Einhorn, Lukas
last_name: Einhorn
- first_name: Judit
full_name: Fazekas, Judit
id: 36432834-F248-11E8-B48F-1D18A9856A87
last_name: Fazekas
orcid: 0000-0002-8777-3502
- first_name: Martina
full_name: Muhr, Martina
last_name: Muhr
- first_name: Alexandra
full_name: Schoos, Alexandra
last_name: Schoos
- first_name: Kumiko
full_name: Oida, Kumiko
last_name: Oida
- first_name: Josef
full_name: Singer, Josef
last_name: Singer
- first_name: Lucia
full_name: Panakova, Lucia
last_name: Panakova
- first_name: Krisztina
full_name: Manzano-Szalai, Krisztina
last_name: Manzano-Szalai
- first_name: Erika
full_name: Jensen-Jarolim, Erika
last_name: Jensen-Jarolim
citation:
ama: Einhorn L, Singer J, Muhr M, et al. Generation of recombinant FcεRIα of dog,
cat and horse for component-resolved allergy diagnosis in veterinary patients.
Journal of Allergy and Clinical Immunology. 2015;135(2). doi:10.1016/j.jaci.2014.12.1263
apa: Einhorn, L., Singer, J., Muhr, M., Schoos, A., Oida, K., Singer, J., … Jensen-Jarolim,
E. (2015). Generation of recombinant FcεRIα of dog, cat and horse for component-resolved
allergy diagnosis in veterinary patients. Journal of Allergy and Clinical Immunology.
Elsevier. https://doi.org/10.1016/j.jaci.2014.12.1263
chicago: Einhorn, Lukas, Judit Singer, Martina Muhr, Alexandra Schoos, Kumiko Oida,
Josef Singer, Lucia Panakova, Krisztina Manzano-Szalai, and Erika Jensen-Jarolim.
“Generation of Recombinant FcεRIα of Dog, Cat and Horse for Component-Resolved
Allergy Diagnosis in Veterinary Patients.” Journal of Allergy and Clinical
Immunology. Elsevier, 2015. https://doi.org/10.1016/j.jaci.2014.12.1263.
ieee: L. Einhorn et al., “Generation of recombinant FcεRIα of dog, cat and
horse for component-resolved allergy diagnosis in veterinary patients,” Journal
of Allergy and Clinical Immunology, vol. 135, no. 2. Elsevier, 2015.
ista: Einhorn L, Singer J, Muhr M, Schoos A, Oida K, Singer J, Panakova L, Manzano-Szalai
K, Jensen-Jarolim E. 2015. Generation of recombinant FcεRIα of dog, cat and horse
for component-resolved allergy diagnosis in veterinary patients. Journal of Allergy
and Clinical Immunology. 135(2), AB101.
mla: Einhorn, Lukas, et al. “Generation of Recombinant FcεRIα of Dog, Cat and Horse
for Component-Resolved Allergy Diagnosis in Veterinary Patients.” Journal of
Allergy and Clinical Immunology, vol. 135, no. 2, AB101, Elsevier, 2015, doi:10.1016/j.jaci.2014.12.1263.
short: L. Einhorn, J. Singer, M. Muhr, A. Schoos, K. Oida, J. Singer, L. Panakova,
K. Manzano-Szalai, E. Jensen-Jarolim, Journal of Allergy and Clinical Immunology
135 (2015).
date_created: 2020-08-10T11:54:09Z
date_published: 2015-02-01T00:00:00Z
date_updated: 2021-01-12T08:17:42Z
day: '01'
doi: 10.1016/j.jaci.2014.12.1263
extern: '1'
intvolume: ' 135'
issue: '2'
language:
- iso: eng
month: '02'
oa_version: None
publication: Journal of Allergy and Clinical Immunology
publication_identifier:
issn:
- 0091-6749
publication_status: published
publisher: Elsevier
quality_controlled: '1'
status: public
title: Generation of recombinant FcεRIα of dog, cat and horse for component-resolved
allergy diagnosis in veterinary patients
type: journal_article
user_id: 2DF688A6-F248-11E8-B48F-1D18A9856A87
volume: 135
year: '2015'
...
---
_id: '8244'
abstract:
- lang: eng
text: Passive immunotherapy with monoclonal antibodies represents a cornerstone
of human anticancer therapies, but has not been established in veterinary medicine
yet. As the tumor-associated antigen EGFR (ErbB-1) is highly conserved between
humans and dogs, and considering the effectiveness of the anti-EGFR antibody cetuximab
in human clinical oncology, we present here a “caninized” version of this antibody,
can225IgG, for comparative oncology studies. Variable region genes of 225, the
murine precursor of cetuximab, were fused with canine constant heavy gamma and
kappa chain genes, respectively, and transfected into Chinese hamster ovary (CHO)
DUKX-B11 cells. Of note, 480 clones were screened and the best clones were selected
according to productivity and highest specificity in EGFR-coated ELISA. Upon purification
with Protein G, the recombinant cetuximab-like canine IgG was tested for integrity,
correct assembly, and functionality. Specific binding to the surface of EGFR-overexpressing
cells was assessed by flow cytometry and immunofluorescence; moreover, binding
to canine mammary tissue was demonstrated by immunohistochemistry. In cell viability
and proliferation assays, incubation with can225IgG led to significant tumor cell
growth inhibition. Moreover, this antibody mediated significant tumor cell killing
via phagocytosis in vitro. We thus present here, for the first time, the generation
of a canine IgG antibody and its hypothetical structure. On the basis of its cetuximab-like
binding site, on the one hand, and the expression of a 91% homologous EGFR molecule
in canine cancer, on the other hand, this antibody may be a promising research
compound to establish passive immunotherapy in dog patients with cancer.
article_processing_charge: No
article_type: original
author:
- first_name: J.
full_name: Singer, J.
last_name: Singer
- first_name: Judit
full_name: Fazekas, Judit
id: 36432834-F248-11E8-B48F-1D18A9856A87
last_name: Fazekas
orcid: 0000-0002-8777-3502
- first_name: W.
full_name: Wang, W.
last_name: Wang
- first_name: M.
full_name: Weichselbaumer, M.
last_name: Weichselbaumer
- first_name: M.
full_name: Matz, M.
last_name: Matz
- first_name: A.
full_name: Mader, A.
last_name: Mader
- first_name: W.
full_name: Steinfellner, W.
last_name: Steinfellner
- first_name: S.
full_name: Meitz, S.
last_name: Meitz
- first_name: D.
full_name: Mechtcheriakova, D.
last_name: Mechtcheriakova
- first_name: Y.
full_name: Sobanov, Y.
last_name: Sobanov
- first_name: M.
full_name: Willmann, M.
last_name: Willmann
- first_name: T.
full_name: Stockner, T.
last_name: Stockner
- first_name: E.
full_name: Spillner, E.
last_name: Spillner
- first_name: R.
full_name: Kunert, R.
last_name: Kunert
- first_name: E.
full_name: Jensen-Jarolim, E.
last_name: Jensen-Jarolim
citation:
ama: Singer J, Singer J, Wang W, et al. Generation of a canine anti-EGFR (ErbB-1)
antibody for passive immunotherapy in dog cancer patients. Molecular Cancer
Therapeutics. 2014;13(7):1777-1790. doi:10.1158/1535-7163.mct-13-0288
apa: Singer, J., Singer, J., Wang, W., Weichselbaumer, M., Matz, M., Mader, A.,
… Jensen-Jarolim, E. (2014). Generation of a canine anti-EGFR (ErbB-1) antibody
for passive immunotherapy in dog cancer patients. Molecular Cancer Therapeutics.
American Association for Cancer Research. https://doi.org/10.1158/1535-7163.mct-13-0288
chicago: Singer, J., Judit Singer, W. Wang, M. Weichselbaumer, M. Matz, A. Mader,
W. Steinfellner, et al. “Generation of a Canine Anti-EGFR (ErbB-1) Antibody for
Passive Immunotherapy in Dog Cancer Patients.” Molecular Cancer Therapeutics.
American Association for Cancer Research, 2014. https://doi.org/10.1158/1535-7163.mct-13-0288.
ieee: J. Singer et al., “Generation of a canine anti-EGFR (ErbB-1) antibody
for passive immunotherapy in dog cancer patients,” Molecular Cancer Therapeutics,
vol. 13, no. 7. American Association for Cancer Research, pp. 1777–1790, 2014.
ista: Singer J, Singer J, Wang W, Weichselbaumer M, Matz M, Mader A, Steinfellner
W, Meitz S, Mechtcheriakova D, Sobanov Y, Willmann M, Stockner T, Spillner E,
Kunert R, Jensen-Jarolim E. 2014. Generation of a canine anti-EGFR (ErbB-1) antibody
for passive immunotherapy in dog cancer patients. Molecular Cancer Therapeutics.
13(7), 1777–1790.
mla: Singer, J., et al. “Generation of a Canine Anti-EGFR (ErbB-1) Antibody for
Passive Immunotherapy in Dog Cancer Patients.” Molecular Cancer Therapeutics,
vol. 13, no. 7, American Association for Cancer Research, 2014, pp. 1777–90, doi:10.1158/1535-7163.mct-13-0288.
short: J. Singer, J. Singer, W. Wang, M. Weichselbaumer, M. Matz, A. Mader, W. Steinfellner,
S. Meitz, D. Mechtcheriakova, Y. Sobanov, M. Willmann, T. Stockner, E. Spillner,
R. Kunert, E. Jensen-Jarolim, Molecular Cancer Therapeutics 13 (2014) 1777–1790.
date_created: 2020-08-10T11:54:29Z
date_published: 2014-07-01T00:00:00Z
date_updated: 2021-01-12T08:17:42Z
day: '01'
doi: 10.1158/1535-7163.mct-13-0288
extern: '1'
intvolume: ' 13'
issue: '7'
language:
- iso: eng
month: '07'
oa_version: None
page: 1777-1790
publication: Molecular Cancer Therapeutics
publication_identifier:
issn:
- 1535-7163
- 1538-8514
publication_status: published
publisher: American Association for Cancer Research
quality_controlled: '1'
status: public
title: Generation of a canine anti-EGFR (ErbB-1) antibody for passive immunotherapy
in dog cancer patients
type: journal_article
user_id: 2DF688A6-F248-11E8-B48F-1D18A9856A87
volume: 13
year: '2014'
...